Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 000-21990

Oncotelic Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		13-3679168
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

29397 Agoura Road Suite 107
Agoura Hills, CA		91301
(Address of principal executive offices)		(Zip Code)

(650) 635-7000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None		OTLC		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 11, 2023, there were 398,159,128 shares of the registrant’s common stock outstanding.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023

TABLE OF CONTENTS

		Page

PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements (unaudited)	3

	Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022	3

	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022	4

	Consolidated Statements of Changes in Stockholders’ Equity for the Three Months and Six Months Ended June 30, 2023 and 2022	5-6

	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022	7

	Notes to Consolidated Financial Statements	8

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	47

ITEM 4.	Controls and Procedures	47

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings	49

ITEM 1A.	Risk Factors	49

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	49

ITEM 3.	Defaults Upon Senior Securities	49

ITEM 4.	Mine Safety Disclosures	49

ITEM 5.	Other Information	49

ITEM 6.	Exhibits, Financial Statement Schedules	49

SIGNATURES		51

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30,			December 31,
	2023			2022

ASSETS
Current assets:
Cash	$	181,872		$	241,452
Restricted cash		20,000		$	20,000
Accounts receivable		18,976			19,748
Prepaid & other current assets		60,736			21,964

Total current assets		281,584			303,164

In process R&D		1,101,760			1,101,760
Goodwill, net of impairment		5,988,230			12,071,376
Investment in GMP Bio at fair value		22,640,519			22,640,519
Total assets	$	30,012,093		$	36,116,819

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	2,458,589		$	2,510,864
Accounts payable to related party		343,001			332,432
Contingent consideration		2,625,000			2,625,000
Derivative liability on notes		525,734			198,140
Convertible and short-term debt, net of costs		10,261,891			10,091,923
Convertible debt and short-term debt - related party, net of costs		1,871,930			1,165,048

Total current liabilities		18,086,145			16,923,407

Stockholders’ equity:
Common stock, $.01 par value; 750,000,000 shares authorized; 397,531,590 and 391,846,880 issued and outstanding, respectively		3,975,316			3,918,469
Additional paid-in capital		41,235,949			41,416,632
Accumulated deficit		(32,896,062	)		(25,926,069	)

Total Oncotelic Therapeutics, Inc. stockholders’ equity		12,315,203			19,409,032
Non-controlling interests		(389,255	)		(215,620	)

Total stockholders’ equity		11,925,948			19,193,412
Total liabilities and stockholders’ equity	$	30,012,093		$	36,116,819

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three MONTHS AND SIX MONTHS ended JUNE 30, 2023 and 2022

(Unaudited)


	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2023			2022			2023			2022

Operating expenses:
Research and development	$	-		$	108,707		$	28,927		$	689,004
General and administrative		238,758			147,608			436,958			3,911,518
Goodwill impairment		6,083,146			-			6,083,146			-
Total operating expenses		6,321,904			256,315			6,549,031			4,600,522

Loss from operations		(6,321,904	)		(256,315	)		(6,549,031	)		(4,600,522	)
Other income (expense):
Reimbursement for expenses - related party		-			247,492			72,246			247,492
Interest expense, net		(257,396	)		(1,094,878	)		(651,675	)		(1,392,341	)
Gain on derecognition of non-financial asset		-			16,951,477			-			16,951,477
Change in fair value of derivative on debt		(307,698	)		122,919			(327,594	)		(67,922	)
Miscellaneous income		36,988			-			-			-
Loss on extinguishment / conversion of debt		-			-			-			(257,810	)
Total other income (expense)		(528,106	)		16,227,010			(907,023	)		15,480,896
Net income (loss) before non-controlling interests		(6,850,010	)		15,970,695			(7,456,054	)		10,880,374
Net loss attributable to non-controlling interests		(93,010	)		(41,424	)		(173,635	)		(281,964	)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.		(6,757,000	)	$	16,012,119		$	(7,282,419	)	$	11,162,338

Basic net income (loss) per share attributable to common stock	$	(0.02	)	$	0.04		$	(0.02	)	$	0.03
Basic weighted average common stock outstanding		394,374,227			379,203,841			393,829,610			378,588,600

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

Consolidated STATEMENT of STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023

(Unaudited)

	Shares		Amount		Shares		Amount		Capital			Deficit			Interests			Equity
	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Non controlling			Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Interests			Equity

Balance at January 1, 2023		-	$	-		391,846,880	$	3,918,469	$	41,416,632		$	(25,926,069	)	$	(215,620	)	$	19,193,412
Adoption of ASU 2020-06										(521,749	)		312,426					$	(209,323	)
Common shares issued upon partial conversion of debt		-				1,025,000		10,250		61,499			-			-			71,749
Net loss		-		-									(525,419	)		(80,625	)		(606,044	)
Balance at March 31, 2023		-		-		392,871,880		3,928,719		40,956,382			(26,139,062	)		(296,245	)		18,449,794

Common shares issued in connection with debt conversion		-		-		4,659,710		46,597		279,567			-			-			326,164
Net income (loss)		-		-		-		-		-			(6,757,000	)		(93,010	)		(6,850,010	)
Balance as of June 30, 2023		-	$	-		397,531,590	$	3,975,316	$	41,235,949		$	(32,896,062	)	$	(389,255	)	$	11,925,948

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

Consolidated STATEMENT of STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

(Unaudited)

	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Non controlling			Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Interests			Equity

Balance at January 1, 2022		-	$	-		375,288,146	$	3,752,881	$	35,223,842		$	(31,021,050	)	$	202,758		$	8,158,431

Common shares issued upon cashless exercise of warrants		-				3,041,958		30,420		(30,420	)		-			-			-
Common shares issued for cash						300,000		3,000		48,805									51,805
Stock compensation expense		-		-		-		-		297,360			-			-			297,360
Warrants issued in connection with note extension		-		-		-		-		2,905,316			-			-			2,905,316
Net loss		-		-									(4,849,781	)		(240,540	)		(5,090,321	)
Balance at March 31, 2022		-		-		378,630,104		3,786,301		38,444,903			(35,870,831	)		(37,782	)		6,322,591
Balance		-		-		378,630,104		3,786,301		38,444,903			(35,870,831	)		(37,782	)		6,322,591

Beneficial Conversion Feature on convertible debt		-		-		-		-		570,717			-			-			570,717
Warrants issued in connection with debt issuance		-		-		-		-		368,375			-			-			368,375
Common shares issued for cash		-		-		300,000		3,000		43,822			-			-			46,822
Common shares issued in connection with debt conversion		-		-		4,525,000		45,250		286,001			-			-			331,251
Common shares issued upon cashless exercise of warrants		-		-		2,586,758		25,867		(25,867	)		-			-			-
Stock compensation expense		-		-		-		-		25,196			-			-			25,196
Contribution from shareholder for payment of liabilities		-		-		-		-		644,463			-			-			644,463
Net income		-		-		-		-		-			16,012,119			(41,424	)		15,970,695
Net income (loss)		-		-		-		-		-			16,012,119			(41,424	)		15,970,695
Balance as of June 30, 2022		-	$	-		386,041,862	$	3,860,418	$	40,357,610		$	(19,858,712	)	$	(79,206	)	$	24,280,110
Balance		-	$	-		386,041,862	$	3,860,418	$	40,357,610		$	(19,858,712	)	$	(79,206	)	$	24,280,110

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

Consolidated STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022

(Unaudited)

	2023			2022
	For the Six Months Ended June 30,
	2023			2022
Cash flows from operating activities:
Net profit	$	(7,456,054	)	$	10,880,374
Adjustments to reconcile net profit to net cash provided by (used in) operating activities:
Gain on derecognition of non-financial asset		-			(16,951,477	)
Goodwill impairment		6,083,146			-
Amortization of debt discount and deferred finance costs		251,782			1,133,270
Amortization of intangible assets		-			12,841
Warrants issued in connection with private placement		-			2,905,316
Stock-based compensation		-			322,556
Change in fair value of derivative		327,594			67,922
Loss on debt conversion		-			257,810
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(38,000	)		(4,932	)
Accounts payable and accrued expenses		117,289			276,704
Accounts payable to related party		14,663			(66,183	)
Net cash provided by (used in) operating activities		(699,580	)		(1,165,799	)

Cash flows from financing activities:
Proceeds from / (repayment to) private placement		(50,000	)		(25,000	)
Proceeds from sales of common stock		-			98,627
Proceeds from convertible debt		-			983,175
Proceeds from short term loans, others		690,000			500,000
Repaid to note holders		-			(500,000	)
Repaid to related party/others		-			(60,000	)
Net cash provided by financing activities		640,000			996,802

Net increase (decrease) in cash		(59,580	)		(168,997	)

Cash and restricted cash - beginning of period		261,452			588,769

Cash and restricted cash - end of period	$	201,872		$	419,772

Supplemental cash flow information:
Cash paid for:
Interest paid	$	197,458		$	328,181
Non-cash investing and financing activities:
Warrants issued in connection with private placement	$	-		$	2,905,316
Contribution from shareholder for payment of liabilities		-			644,463
Common shares issued upon conversion of debt	$	397,912		$	650,001
Beneficial Conversion Feature on convertible debt and restricted common shares	$	-		$	570,717
Adoption of ASU 2020-06, net	$	(209,323	)	$	-

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

Oncotelic Therapeutics, Inc. (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation: and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and Edgepoint are collectively called the “Company” or “We”). The Company completed a reverse merger with Oncotelic Inc in April 2019, a merger with PointR in November 2019 and formed a subsidiary Edgepoint in February 2020. For more information on these mergers, refer to our 2020 Annual Report on Form 10-K filed with the SEC on April 15, 2021.

The Company is currently developing OT-101, through its joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), both affiliates of Golden Mountain Partners (“GMP”), for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The Company is also independently planning to develop OT-101 for certain animal health indications and contemplating using crypto currencies for that platform. The Company has acquired apomorphine for Parkinson’s Disease, erectile dysfunction and female sexual dysfunction. In addition, the Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.

The Company is primarily a cancer immunotherapy company dedicated to the development of first in class self-immunization protocol (“SIP™”) candidates for difficult to treat cancers. The Company’s proprietary SIP™ candidates are expected to offer advantages over other immunotherapies because they do not require extraction of the tumor or isolation of the antigens, and they have the potential for broad-spectrum applicability for multiple cancer types. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by TGF-β overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy (“DMD”) and others. OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. The JV plans to initiate phase 2 and 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer, and any other indications that may evolve, for human pharmaceutical needs. The JV will also be sponsoring many investigator-initiated studies for OT-101 for other oncology indications. The Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The JV is also developing OT-101 for the various epidemics and pandemics, similar to the current corona virus (“COVID-19”) pandemic. In this connection, the Company entered into an agreement and supplemental agreement with GMP for a total of $1.2 million to render services and was paid for the development of OT-101. The Company is working with the Biomedical Advanced Research and Development Authority to conduct an observational study to evaluate the effects of long Covid-19 and has been provided a grant of up to $0.75 million for the study. In 2020 and 2021, the Company was developing Artemisinin as a potential therapy for COVID-19. Artemisinin, purified from a plant Artemisia annua. For more information on GMP and Artemisinin, refer to our 2022 Annual report on Form 10-K/A filed with the SEC on April 19, 2023.

Fundraising

J.H. Darbie Financing Notes & Issuance of Oncotelic Warrants

In February 2022, the Company and 99 out of 100 of the Investors agreed to extend the maturity date of the notes connected to the Units from March 31, 2022 to March 31, 2023. In addition, the Company issued approximately 33 million warrants to purchase $50,000 of shares of common stock of the Company in connection with agreeing to extend the maturity date by one year. The issuance of the additional warrants resulted in the Company recording an expense of approximately $2.9 million in the Company’s statement of operations during the year ended December 31, 2022. For more information on the JD Darbie financing, refer to Note 7 of these unaudited Notes to the Consolidated Financial Statements. In July 2023, the Company commenced a new private placement financing through JH Darbie, and converted the debt of 15 accredited investors into the current Subscription Agreements, which resulted in conversion of $1.0 million of debt to the Company. These debt conversions were for the prior private placement by JH Darbie. As of the date of this filing, we are working on getting the balance note holders from the prior JH Darbie Financing converted into the new JH Darbie Financing. For more information on the new JH Darbie Financing, refer to Note 14 of these Notes to Consolidate Financial Statements.

Equity Purchase Agreement

In May 2021, the Company entered into an Equity Purchase Agreement (the “EPL”) and Registration Rights Agreement (the “Registration Rights Agreement”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company shall have the right, but not the obligation, to direct Peak One to purchase up to $10.0 million (the “Maximum Commitment Amount”) in shares of the common stock, par value $0.01 per share (“Common Stock”) in multiple tranches. The Company filed a post-effective amendment to reregister the EPL on April 26, 2022 and the post-effective amendment was found effective by the SEC on May 6, 2022. Since the EPL was made effective in June 2021 till December 31, 2022, the Company has directed Peak One, on multiple occasions, for an aggregate of 4.7 million shares of Common Stock for aggregate net cash proceeds of approximately $0.6 million. The Company filed a new post-effective amendment in April 2023 and the new post-effective amendment was found effective on April 25, 2023. The Company also filed a final form 424b3 Prospectus with the SEC on May 2, 2023. For more information on the EPL, refer to Note 9 of the Notes to the Consolidated Financial Statements.

August 2021 Notes

In August 2021, the Company issued Note Purchase Agreements with Autotelic Inc., the Company’s Chief Financial Officer (“CFO”), and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 (the “Principal Amount”) in debt in the form of unsecured convertible promissory notes (collectively, the “Notes”). The Notes are unsecured, and provide for interest at the rate of 5% per annum. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

November-December 2021 and March 2022 Notes

In November / December 2021, the Company entered into various Securities Purchase Agreements with Talos Victory Fund, LLC (the (“Talos”), Mast Hill Fund, LP (“Mast”), FirstFire Global Opportunities Fund, LLC (“FirstFire”), Blue Lake Partners, LLC (“Blue Lake”) and Fourth Man, LLC (“Fourth Man”), pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.25 million each, aggregating gross $1.25 million (the “Notes”), and which Notes were convertible into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). As of December 31, 2022, two of these notes were in default and available for conversion to OTLC shares due to cross default provision contained in November / December 2021 Notes. As of the date of this Report on Form 10-Q, all the Notes under the November-December 2021 Notes are fully converted.

In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $0.25 million, which Note is convertible into shares of the Company’s Common Stock. As of March 31, 2023, this note is in default and available for conversion to OTLC shares due to cross default provision contained in November / December 2021 Notes.

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

May 2022 Note

In May 2022, the Company entered into a Securities Purchase Agreement with Mast, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.6 million, which note is convertible into shares of the Company’s Common Stock. As of December 31, 2022, this note is in technical default and available for conversion to OTLC shares due to cross default provision contained in November / December 2021 Notes. This note was used to fully repay November 2021 Talos note and the December 2021 First Fire note. $35,000 of the First Fire Note was converted into 500,000 shares of Common Stock and the balance was repaid in cash

In June 2022, Mast fully converted their November 2021 Note, for which the company issued 4,025,000 shares of Common Stock.

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

June 2022 Note

In June 2022, the Company entered into a Securities Purchase Agreement with Blue Lake, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.34 million, which note is convertible into shares of the Company’s Common Stock.

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

GMP Note purchase agreements and unsecured notes

In August 2021 the Company, the Company’s Chief Executive Officer (the “CEO”), and GMP executed a letter of intent and a non-binding term sheet (the “Term Sheet”), which Term Sheet included certain binding terms relating to a standstill agreement and the issuance of a convertible promissory note (as more fully described below).

Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $4.5 million.

For more information on the GMP debt financing, refer to Note 5 of the unaudited Notes to the Consolidated Financial Statements.

Joint Venture with GMP Bio

In March 2022, the Company formalized a joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), both affiliates of GMP. Although no assurances can be given, the Company and GMP currently intend to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange.

For more information on the JV, refer to Note 6 of the unaudited Notes to the Consolidated Financial Statements.

Pet2DAO

In November 2022, the Company formed a Decentralized autonomous organization (“DAO”) entity, Pet2DAO LLC (“Pet2DAO”), as a wholly owned subsidiary. A DAO is an emerging form of legal structure, that has no central governing body, and whose members share a common goal to act in the best interest of the entity. Pet2DAO is a DAO technology company, integrating the strong governance of traditional corporations with the innovative DAO architecture. The Company will look to engage stakeholders, to build value through the DAO, while maintaining the rigor of traditional corporations, including governance, compliance, and accountability through a team of veterans in public companies with innovators in AI, blockchain and Web3. Pet2DAO will initially be looking to develop products for the animal health space. The Company will initially issue regular tokens and non-fungible tokens (“NFT” and cumulatively “Tokens”) of Pet2DAO called PDAO to its employees, shareholders and key opinion leaders (“KOLs’) and use the Tokens to propose and vote on various animal health related programs. In the future, the Company will evaluate and plan to register these tokens with the SEC to make such Tokens freely tradable at a future point in time.

Principles of Consolidation

The consolidated financial statements include the accounts of Oncotelic, its wholly owned subsidiaries, Oncotelic Inc. and PointR, and Edgepoint our non-controlled interest entity. Intercompany accounts and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-Q and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly state the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been omitted pursuant to such rules and regulations.

Liquidity and Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net accumulated losses of approximately $32.9 million since inception of Oncotelic Inc., as the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic Inc. The Company also has a negative working capital of approximately $17.8 million at June 30, 2023, of which approximately $2.6 million contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company has negative cash flows from operations for the six months ended June 30, 2023 of approximately $0.7 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing Management expects to incur significantly lower costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the need to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The Company’s long-term plans include continued development of its current pipeline of products, in addition to continue the development of OT-101, which is exclusively out-licensed to the JV and the JV will be responsible for the cash required to support the development in entirety, to generate sufficient revenues, through either technology transfer or product sales, to cover its anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments.

Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates.

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.

Cash

As of June 30, 2023, and December 31, 2022 the Company held all its cash in banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2023 and December 31, 2022, respectively. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.

Debt issuance Costs and Debt discount

Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount.

Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction.

If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring.

Fair Value of Financial Instruments

The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

●

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

●

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

●

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

Investment in equity securities

The following table summarizes the cumulative gross unrealized gains and losses and fair values for long-term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of June 30, 2023 and December 31, 2022.:

			Cumulative		Cumulative
			Gross		Gross
	Initial		Unrealized		Unrealized		Fair
	Book Value		Gains		Losses		Value
June 30, 2023 and December 31, 2022
Investment in GMP Bio (equity securities)	$	22,640,519	$	-	$	-	$	22,640,519
Total	$	22,640,519	$	-	$	-	$	22,640,519

The table below sets forth a summary of the changes in the fair value of the Company’s long-term investment in equity securities, based on a third-party valuation report, as a Level 3 fair value as of June 30, 2023 and December 31, 2022:

	June 30, 2023		December 31, 2022
Balance at January 1, 2023 and 2022	$	22,640,519	$	-
Contribution at cost basis		-		5,689,042
Gain on derecognition of non-financial asset		-		16,591,477
Change in fair value		-		-

Balance at June 30, 2023 and December 31, 2022	$	22,640,519	$	22,640,519

Derivative Liability

The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), which consisted of conversion feature derivatives at June 30, 2023 and December 31, 2022, are Level 3 fair value measurements.

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of June 30, 2023 and 2022:

	June 30, 2023		June 30, 2022
	Conversion Feature		Conversion Feature
Balance at January 1, 2023 and 2022	$	198,140	$	340,290
New derivative liability				-
Reclassification to additional paid in capital from conversion of debt to common stock				-
Change in fair value		327,594		67,922

Balance at June, 2023 and 2022	$	525,734	$	408,212

As of June 30, 2023, and 2022, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of June 30, 2023 and 2022, respectively:

	June 30, 2023			June 30, 2022
	Key			Key
	Assumptions			Assumptions
	for fair value			for fair value
	of conversions			of conversions
Risk free interest		5.4	%		0.17% -1.03%
Market price of share	$	0.03		$	0.17-0.23
Life of instrument in years		0.01			0.01 – 0.33
Volatility		171.25	%		107.50%-109.40%
Dividend yield		0	%		0	%

When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended June 30, 2023 and 2022, respectively, there were no transfers of financial assets or financial liabilities between the hierarchy levels.

The $2,625,000 of contingent consideration, of shares issuable to PointR shareholders which was recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic. As such, the Company did not record any change to the valuation during the six months ended June 30, 2023 or 2022, respectively.

Net Income (Loss) Per Share

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. For the three and six months ended June 30, 2023, no equivalent shares of the Common Stock were excluded as the company has a loss and addition of such stock equivalents in the computation would have been anti-dilutive.

Stock-Based Compensation

The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations.

For stock options issued to employees and members of the Board of Directors (the “Board”) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.

For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If, however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital.

Impairment of Long-Lived Assets

The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and six months ended June 30, 2023 and the year ended December 31, 2022, there were no impairment losses recognized for long-lived assets.

Intangible Assets

The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the three and six months ended June 30, 2023 and 2022, respectively, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. For the three and six months ended June 30, 2022, we derecognized the intangibles of $0.8 million associated with OT-101 upon the transfer of our non-financial asset as a capital contribution for our 45% ownership in the JV.

Goodwill

Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach.

The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. As such, for the three and six months ended June 30, 2023 we recorded an impairment loss of approximately $6.1 million on our goodwill. No similar impairment was recorded for the three or six months ended June 30, 2022. For the year ended December 31, 2022 we had recorded an impairment loss of approximately $4.1 million on our goodwill and derecognized the goodwill of $4.8 million associated with OT-101 upon the transfer of our non-financial asset as a capital contribution for our 45% ownership in the JV. For more information on goodwill and impairment, refer to Note 3 to these Notes to the Consolidated Financial Statements.

Derivative Financial Instruments Indexed to the Company’s Common Stock

We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Income.

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.”

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Variable Interest Entity (VIE) Accounting

The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At June 30, 2023 and December 31, 2022, the Company identified EdgePoint to be the Company’s sole VIE. At June 30, 2023 and December 31, 2022, the Company’s ownership percentage of EdgePoint was 29% and 29%, respectively. The VIE’s net assets were less than $0.1 million at June 30, 2023 and December 31, 2022, respectively.

Investments - Equity Method

The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the Consolidated Financial Statements.

Joint Venture agreement

We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture.

We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination.

To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non-managing entity and the inability of the non-managing entity to remove us from our role as the managing entity.

We use the equity method of accounting for those arrangements where we exercise significant influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our consolidated balance sheet.

When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss.

When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value.

The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the company.

Embedded debt costs in convertible debt instruments

In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition was permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted no earlier than the fiscal year beginning after December 15, 2020. The Company has adopted ASU 2020-06 effective January 1, 2023.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (Topic 606).

Under Topic 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of Topic 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company anticipates generating revenues from rendering services to other third-party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either upon achievement of certain pre-defined milestones, when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations.

The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

Research & Development Costs

In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Recent Accounting Pronouncements

All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

NOTE 3 - INTANGIBLE ASSETS AND GOODWILL

Goodwill from 2019 Reverse Merger with Oncotelic and PointR

The Company completed the merger with Oncotelic Inc. (“Merger”) in April 2019. The Company completed the merger with PointR Data Inc (“PointR Merger”) in November 2019. For more details, refer to our 2020 Annual Report on Form 10-K for the year ended December 31, 2020 filed by the Company on April 15, 2021.

The Oncotelic merger gave rise to Goodwill of approximately $4.9 million. Upon the non-financial sale of our asset as contribution to our equity method investment, we derecognized the balance of the carrying value of our goodwill of approximately $4.9 million from the Oncotelic Merger in accordance with our policy and authoritative accounting guidance.

Further, we added goodwill of $16,182,456 upon the completion of the Merger with PointR.

We have one operating segment and reporting unit. Accordingly, our review of goodwill impairment indicators was performed at the entity-wide level. In performing our annual impairment assessment, we determined if we should qualitatively assess whether it was more likely than not the fair value of goodwill was less than its carrying amount (the qualitative impairment test). The factors we considered in the assessment included our market capitalization, general macroeconomic conditions, conditions specific to the industry and market and whether there had been sustained declines in our share price. If we concluded, it was more likely than not, the fair value of the reporting unit was less than its carrying amount, or elected not to use the qualitative impairment test, a quantitative impairment test would be performed.

We used, and will continue to use, our market capitalization as an indicator of fair value. While we believe the fair value measurement need not be based solely on the quoted market price of an individual share of our Common Stock, and that we also could consider the impact of a control premium in measuring the fair value of its reporting unit. In the absence of any other valuation metrics, the Company believed using a control premium utilized would not be appropriate under the current circumstances. We also considered some other market comparable’ trends in our stock price, as well as the industry, over a period of two successive quarters and prospective quarter to evaluate whether the fair value of our reporting unit was greater than our carrying amount. As such, we performed a quantitative impairment assessment of goodwill for our single reporting unit at the end of 2022, due to a sustained decline in our market capitalization and an increase in negative economic outlook for biotech markets We estimated and reconciled the fair value of our reporting unit utilizing our market capitalization based on the stock price of our Common Stock as of December 31, 2022. Before completing our goodwill impairment test, we first tested our indefinite-lived intangible asset then our remaining long-lived assets for impairment. We concluded our indefinite-lived intangible assets were not impaired. Based on the market capitalization, we further concluded the fair value of our single reporting unit was less than its carrying value and therefore recognized an impairment charge of $4.1 million during the year ended December 31, 2022. The calculation of the impairment charge included substantial fact-based determinations and estimates.

A summary of our goodwill as of June 30, 2023 and December 31, 2022 is shown below:

SUMMARY OF GOODWILL

	June 30,			December 31,
	2023			2022
Balance at beginning of the year	$	12,071,376		$	21,062,455
Less: Derecognition upon recording of gain on non-financial asset		-			(4,880,000	)
Less;: Goodwill impairment due to market capitalization		(6,083,146	)		(4,111,079	)

Balance at the end of the period	$	5,988,230		$	12,071,376

In general, the goodwill is tested on an annual impairment date of December 31, unless we observe any further deterioration in our market capitalization, in which case we may, depending on the materiality of the impairment, record an impairment at the end of other reporting periods. Since we observed a significant drop in the stock price of our Common Stock, we assessed that an additional impairment needed to be recorded, solely based on the market capitalization of our stock as of June 30, 2023 as compared to December 31, 2022. as such, the Company concluded that an additional impairment was required to be recorded for the three and six months ended June 30, 2023 of approximately $6.1 million. No similar impairment was recorded during the six months ended June 30, 2022.

Assignment and Assumption Agreement with Autotelic, Inc.

In April 2018, Oncotelic Inc. entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Autotelic Inc., an affiliate company, and Autotelic LLC, an affiliate company, pursuant to which Oncotelic acquired the rights to all intellectual property (“IP”) related to a patented product. As consideration for the Assignment Agreement, Oncotelic Inc. issued 204,798 shares of its Common Stock for a value of $819,191. The Assignment Agreement also provides that Oncotelic Inc. shall be responsible for all costs related to the IP, including development and maintenance, going forward. After the formation of the JV with Dragon, the costs of development and maintenance are now the responsibility of the JV.

Intangible Asset Summary

The following table summarizes the balances as of December 31, 2022, of the intangible assets acquired, their useful life, and annual amortization. As the intangible assets acquired were already derecognized as of December 31, 2023, we had no similar assets or adjustments thereto as of June 30, 2023:

SCHEDULE OF INTANGIBLE ASSETS

	December 31, 2022			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual property	$	819,191
Intangible asset – Capitalization of license cost		190,989
		1,010,180
Less Accumulated Amortization		(201,180	)
Less: Derecognition of carrying value upon transfer of non-financial asset		(809,000	)
Total	$	-

Amortization of identifiable intangible assets for the three months ended June 30, 2023 and 2022 was $0. Amortization of identifiable intangible assets for the six months ended June 30, 2023 and 2022 was $0 and $12,841, respectively. Upon the sale of our non-financial sale, as the contribution to our equity method investment of approximately $809,000, we derecognized the balance of the carrying value of our intangibles in accordance with our policy and authoritative accounting guidance.

There will be no future yearly amortization expense related to our intangibles.

In-Process Research & Development (“IPR&D”) Summary

The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of June 30, 2023 and December 31, 2022 was $1,101,760. For more information on the IPR&D, please refer to our 2022 Annual Report on Form 10-K filed with the SEC on April 14, 2023 or our Amended 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expense consists of the following amounts:

	June 30,		December 31,
	2023		2022
Accounts payable	$	1,682,943	$	1,735,764
Accrued expense		775,646		775,100
	$	2,458,589	$	2,510,864

	June 30, 2023		December 31, 2022

Accounts payable – related party	$	343,001	$	332,432

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT

As of June 30, 2023 special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts:

	June 30,		December 31,
	2023		2022
Convertible debentures
10% Convertible note payable, due April 23, 2022 – Bridge Investor	$	35,556	$	35,556
10% Convertible note payable, due April 23, 2022 – Related Party		164,444		164,444
10% Convertible note payable, due August 6, 2022 – Bridge Investor		200,000		200,000
		400,000		400,000
Fall 2019 Notes
5% Convertible note payable – Stephen Boesch		126,458		123,958
5% Convertible note payable – Related Party		294,983		288,733
5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)		294,503		288,253
5% Convertible note payable – CEO, CTO* & CFO – Related Parties		96,509		94,457
5% Convertible note payable – Bridge Investors		197,722		193,522
		1,010,175		988,923
August 2021 Convertible Notes
5% Convertible note – Autotelic Inc– Related Party		273,802		267,553
5% Convertible note – Bridge investors		409,061		399,722
5% Convertible note – CFO – Related Party		82,142		80,266
		765,005		747,541
JH Darbie PPM Debt
16% Convertible Notes - Non-related parties		2,397,238		2,441,471
16% Convertible Notes – CEO – Related Party		125,000		124,547
		2,522,238		2,566,018
November/December 2021 & March 2022 Notes
16% Convertible Notes – Accredited Investors		323,622		619,345

Debt for Clinical Trials – GMP
2% Convertible Notes – GMP		4,704,631		4,659,782

May and June 2022 Note
16% Convertible Notes – Accredited Investors		1,286,809		885,312

Other Debt
Short term debt – Bridge investors		245,000		245,000
Short term debt from CFO		35,050		25,050
Short term debt – Autotelic Inc– Related Party		800,000		120,000
		1,080,050		390,050
Accrued interest		58,791		-
Total of convertible debentures & notes and other debt	$	12,133,821		11,256,971

Bridge Financing

Notes with Officer and Bridge Investor

In April 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO (the “Trieu Note”) and a Bridge Investor with a commitment to purchase convertible notes in the aggregate of $400,000. For more information on the Bridge SPA, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

The issuance of the Trieu Note resulted in a discount from the beneficial conversion feature totaling $131,555 related to the conversion feature. Total amortization of the OID and the discount totaled $0 and $19,493 for the six months ended June 30, 2023, and 2022, respectively. Total unamortized discount on this note was approximately $0 as of June 30, 2023, and December 31, 2022.

In April 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. For more information on Tranche #1, refer to our Annual Report on Form 10-K filed with the SEC on April 14, 2023.

The issuance of the note resulted in a discount from the beneficial conversion feature totaling $28,445. Total amortization of the OID and discount totaled approximately $0 and $4,400 for the six months June 30, 2023, and 2022, respectively. Total unamortized discount on this note was approximately $0 as of June 30, 2023, and December 31, 2022.

On August 6, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. For more information on Tranche #2, refer to our Annual Report on Form 10-K filed with the SEC on April 14, 2023.

The issuance of the note resulted in a discount from the beneficial conversion feature totaling $175,000. Total amortization of the OID and discount totaled approximately $0 and $10,000 for the six months ended June 30, 2023, and 2022, respectively. Total unamortized discount on this note was $0 as of June 30, 2023, and December 31, 2022.

As of June 30, 2023, the Company had a derivative liability of approximately $525,000 and recorded a change in fair value of approximately $327,000 on the Convertible Debentures issued in 2019 to our CEO and a bridge investor.

Fall 2019 Debt Financing

In December 2019, the Company closed its Fall 2019 Debt Financing, raising an additional $500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. The Company issued Fall 2019 Notes in the principal amount of $250,000 to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, the Company issued Fall 2019 Notes to additional investors including $250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, then Company’s Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer, all related parties as Officers of the Company, and converted such amounts due into the Fall 2019 Notes. $35,000 due to Dr. Vuong Trieu, $27,000 due to Chulho Park and $20,000 due to Amit Shah were converted into debt. The Company also issued the Fall 2019 Notes of $168,000 to two accredited investors.

The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of June 30, 2023, and December 31, 2022.

The Company recorded interest expense of $10,625 and $21,250 on these Fall 2019 Notes for the three and six months ended June 30, 2023. Similarly, the Company recorded interest expense of $10,625 and $21,250 for the three and six months ended June 30, 2022 on the Fall 2019 Notes. The total amount outstanding under the Fall 2019 Notes, net of discounts and including accrued interest thereon, as of June 30, 2023 and December 31, 2022, was $1,010,175 and $988,923, respectively.

GMP Notes

In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. The GMP Note is convertible into the Company’s Common Stock upon the GMP Note’s maturity of the GMP Note, at the Company’s Common Stock price on the date of conversion with no discount. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2023. GMP does not have the option to convert prior to the GMP Note’s maturity. Such financing will be utilized solely to fund the clinical trial. The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. GMP has been invoiced by the clinical research organization for the full $2 million as of March 31, 2022, and as such the Company has recognized the liability as a convertible debt.

In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest. The GMP Note is convertible into the Company’s Common Stock upon the GMP Note 2’s maturity one year from the date of the GMP Note 2, at the Company’s Common Stock price on the date of conversion with no discount. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2023. GMP does not have the option to convert prior to the GMP Note 2’s maturity at the end of one year. Such financing was to be utilized solely to fund the clinical trial. As of March 31, 2023, GMP was invoiced by the clinical research organization for $1.5 million. Till date, GMP paid the clinical trial organization the $1.0 million.

In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million (the “October 2021 Note”), which October 2021 Note is convertible into shares of the Company’s Common Stock. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2023.

In January 2022, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “January Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million (the “January 2022 Note”), which January 2022 Note is convertible into shares of the Company’s Common Stock. GMP agreed to extend the date of maturity of the January 2022 Note to December 31, 2023.

Cumulatively, the GMP Note, GMP Note 2, October 2021 Note and the January 2022 Notes are referred to as the “GMP Notes”.

The GMP Notes carry an interest rate of 2% per annum and mature on the earlier of (a) the one-year anniversary of the date of the Purchase Agreement, or (b) the acceleration of the maturity by GMP upon occurrence of an Event of Default (as defined below). All Notes contain a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of all the GMP Notes into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion from GMP. Prepayment of the GMP Notes may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The October Note contains customary events of default (each an “Event of Default”). If an Event of Default occurs, at GMP’s election, the outstanding principal amount of the GMP Notes, plus accrued but unpaid interest, will become immediately due and payable in cash. The October Purchase Agreement requires the Company to use of the proceeds received under the October 2021 Note to support the clinical development of OT-101, including payroll and has been made in continuation of the relationship between the Company and GMP.

The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $4.7 million as of June 30, 2023, and December 31, 2022, respectively.

During the three and six months ended June 30, 2023, the Company incurred approximately $22,438 and $44,850 of interest expense, respectively. During the three and six months ended June 30, 2022, the Company incurred approximately $22,440 and $44,630 of interest expense, respectively.

August 2021 Notes

In August 2021, the Company entered into Note Purchase Agreements with Autotelic - a related party, our CFO - a related party, and certain accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into shares of common stock of the Company for net proceeds of $690,825. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18. The August 2021 Note Holders has waived the default in the maturity of the August 2021 Notes and as such there is no event of default and also agreed to extend the date of maturity of the August 2021 Notes to December 31, 2023. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity.

As of June 30, 2023, and December 31, 2022, the August 2021 convertible notes, inclusive of accrued interest, consist of the following amounts:

	June 30,		December 31,
	2023		2022

Autotelic Related party convertible note, 5% coupon August 2022	$	273,802	$	267,553
CFO Related party convertible note, 5% coupon August 2022		409,061		399,722
Accredited investors convertible note, 5% coupon August 2022		82,142		80,266
	$	765,005	$	747,541

During the three and six months ended June 30, 2023, the Company recognized approximately $8,730 and $17,460 of interest expense on the August 2021 Investors notes, of which approximately $4,060 and $8,125 are attributable to related parties, respectively.

At June 30, 2023, and December 31, 2022, accrued interests on these convertible notes totaled approximately $66,500 and $49,040, respectively.

November – December 2021 and March 2022 Financing

In November and December 2021, the Company entered into securities purchase agreement with five institutional investors, whereby the Company issued five convertible notes in the aggregate principal amount of $1,250,000 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Investors has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.07. The Company granted a total number of 9,615,385 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.13 up to five years after issuance. The Placement agent was also granted a total amount of 961,540 as part of a finder’s fee agreement.

Further, in March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $0.25 million, convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Investors has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.10. The Company granted a total number of 1,250,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total amount of 125,000 as part of a finder’s fee agreement.

As of June 30, 2023, and December 31, 2022, convertible notes under the November-December 2021 Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022
Blue Lake Partners LLC Convertible note, 16% coupon, December 2021 (In default and inclusive of accrued interest)		-			227,817
Fourth Man LLC Convertible note, 16% coupon December 2022 (In default and inclusive of accrued interest)		37,030			112,500
Convertible notes, gross	$	37,030		$	339,687
Less: Debt discount recorded		(500,000	)		(500,000	)
Amortization debt discount		500,000			500,000
Convertible notes, net	$	37,030		$	339,687

The Company recognized approximately $8,600 and $18,300 of interest during the three and six months ended June 30, 2023, respectively. The Company recognized approximately $33,000 and $112,600 of interest during the three and six months ended June 30, 2022, respectively.

The balance of accrued interest was approximately $4,530 and $30,000 as of June 30, 2023, and December 31, 2022, respectively. In July 2023, Fourth Man converted their remaining principal balance, accrued interest and legal fees of approximately $44,000 of their December 2021 Note in exchange for 627,538 shares of our Common Stock. As such, post the close of the six months ended June 30, 2023, the balance due to Fourth Man, post their conversion, on their December 2021 Note is $0.

The Company recognized approximately $0 and $657,400 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants and the beneficial conversion feature during the six months ended June 30, 2023 and 2022, respectively.

The Company recorded an initial debt discount of approximately $0.4 million representing the intrinsic value of the conversion option embedded in the convertible debt instrument based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $0 and $0.5 million for the six months ended June 30, 2023, and 2022, which is included in interest expense in the consolidated statements of operations.

The note includes a default amount calculated at 125% of the unpaid principal and accrued interest. As the Company failed to repay the two notes at maturity date, the Company accrued an additional $68,000 resulting from this default feature, which is included in the consolidated balance sheets as of June 30, 2023 and December 31, 2022. The balance of the default feature was $22,500 at June 30, 2023.

As of June 30, 2023, and December 31, 2022, Fourth Man convertible note, net of debt discount, consist of the following amounts:

	June 30,		December 31,
	2023		2022
Fourth Man Convertible note, 12% coupon March 2022 (Inclusive of interest and default provision)	$	286,593	$	340,959
Unamortized debt Discount		-		(61,301	)

Convertible notes, net	$	286,593	$	279,658

As of June 30, 2023, the balance includes the remaining principal of $210,000, accrued interest of $8,400 and approximately $68,000 of accrued default penalty pursuant to the terms of the underlying agreement.

Accrued interest was approximately $8,400 and $22,800 at June 30, 2023 and December 31, 2022, respectively.

The Company recognized approximately $8,400 and $15,600 of interest during the three and six months ended June 30, 2023, respectively. The Company recognized approximately $7,650 of interest during the three and six months ended June 30, 2022, respectively.

The Company recognized approximately $35,813 and $63,700 of interest expense attributable to the amortization of the debt discount from the original deferred financing costs, fair value allocated to the warrants and the beneficial conversion feature (prior to the adoption of ASU 2020-06) during the six months ended June 30, 2023 and 2022, respectively.

As of June 30, 2023, and December 31, 2022, the balance of the unamortized debt discount was $0 and $61,301, respectively. The Company adopted ASU 2020-06 on January 1, 2023, which resulted in the reversal of the original BCF amount to additional paid in capital for $109,349, reversal of the unamortized debt discount related to the BCF for $25,489 with the balance being recorded through retained earnings for $78,460.

During the six months ended June 30, 2023, the Company converted $40,000 in principal and $30,000 in accrued interest into 1,025,000 shares of common stock. The note includes a default amount calculated at 125% of the unpaid principal and accrued interest. As the Company failed to repay the note at maturity date, the Company accrued an additional $70,000 resulting from this default feature.

May 2022 Mast Financing

In May 2022, the Company entered into a securities purchase agreement with one institutional investor, whereby the Company issued one convertible note in the aggregate principal amount of $605,000 convertible into shares of common stock of the Company (“May 2022 Mast Note”). The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Investor has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.10. The Company granted a total number of 3,025,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total amount of 302,500 as part of a finder’s fee agreement. Portion of the proceeds will be used to retire some of the November/December 2021 notes. The extinguishment of existing notes resulted in the recognition of approximately $258,100 in loss on extinguishment of debt in the consolidated statement of operations in the six months ended June 30, 2022.

As of June 30, 2023, and December 31, 2022, the May 2022 Mast Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022

Mast Hill Convertible note, 16% coupon May 2023, inclusive of accrued interest and penalty	$	857,084		$	847,000
Convertible notes, gross	$	857,084		$	847,000
Less Debt discount recorded		(605,000	)		(605,000	)
Amortization debt discount, net of reversal of original and unamortized BCF		565,725			333,119
Convertible notes, net	$	817,809		$	575,119

Accrued interest was $80,667 and $72,600 as of June 30, 2023 and December 31, 2022, which is the guaranteed twelve-month coupon and earned in full at issuance date and additional coupon at the default rate since the May 2022 Mast financing is past maturity and in default as of June 30, 2023. The Company recognized approximately $56,464 and $146,461 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants during the three and six months ended June 30, 2023, respectively. The Company recognized approximately $53,257 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants and the beneficial conversion feature during the three and six months ended June 30, 2022.

Effective January 1, 2023, the Company adopted ASU 2020-06, which resulted in the reversal of the original BCF amount to additional paid in capital for approximately $0.2 million, a reversal of the unamortized debt discount related to the BCF for approximately $0.1 million, with the balance of approximately $0.1 million being recorded through retained earnings.

June 2022 Financing

In June 2022, the Company entered into a securities purchase agreement with one institutional investor, whereby the Company issued one convertible note in the aggregate principal amount of $335,000 convertible into shares of common stock of the Company (“June 2022 Blue Lake Note”). The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Investor has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $0.10. The Company granted a total number of 837,500 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total amount of 83,750 warrants as part of a finder’s fee agreement. Portion of the proceeds will be used to retire some of the November/December 2021 notes.

As of June 30, 2023, and December 31, 2022, convertible note under the June 2022 Blue Lake Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022

Blue Lake Convertible note, 16% coupon June 2023, inclusive of accrued interest	$	469,000		$	469,000
Convertible notes, gross	$	469,000		$	469,000
Less Debt discount recorded		(332,748	)		(332,748	)
Amortization debt discount, net of reversal of original and unamortized BCF		332,748			173,941
Convertible notes, net	$	469,000		$	310,193

The Company recognized approximately $29,408 and $61,642 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants during the three and six months ended June 30, 2023, respectively. The Company recognized approximately $7,305 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants and BCF (prior to adoption of ASU 2020-06) during the three and six months ended June 30, 2022. The Company adopted ASU 2020-06 effective January 1, 2023, which resulted in the reversal of the original BCF amount to additional paid in capital of approximately $0.2 million, reversal of the unamortized debt discount of approximately $0.1 million related to the BCF and the balance of $0.1 million being recorded through retained earnings. As of June 30, 2023, these notes are in default. However, the Company has not received notification of default from the lender. The Company has recorded an estimated default penalty of approximately $94,000.

Other short-term advances

As of June 30, 2023 compared to December 31, 2022, other short-term advances consist of the following amounts obtained from various employees and related parties:

SCHEDULE OF SHORT-TERM LOANS

Other Advances	June 30, 2022		December 31, 2022
Short term advance from CFO – Related Party	$	35,050	$	25,050
Short term advances – bridge investors & others		245,000		245,000
Short term advance – Autotelic Inc. – Related Party		800,000		120,000
Short term advance	$	1,080,050	$	390,050

During the year ended December 31, 2021, the Company’s CFO provided short term advances of approximately $45,000. Of that amount, $20,000 was repaid to the CFO in January 2022. In the six months ended June 30, 2023, the company’s CFO provided additional short-term advance of $10,000. As such approximately $35,000 was outstanding at June 30, 2023.

During the year ended December 31, 2021, the CFO provided a total of approximately $120,000, of which $75,000 was converted into the August 2021 Notes. During the year ended December 31, 2021, the Company received approximately $630,000 primarily from two bridge investors, of which $373,500 was converted into the August 2021 Notes, and $20,000 was repaid. During the six months ended June 2023, an additional $17,500 was repaid to one of the bridge investors. Approximately $228,000 was outstanding as short-term advances from bridge investors as of June 30, 2023.

In May 2021, Autotelic provided an additional short-term funding of $250,000 to the Company, which was converted into the August 2021 Notes. Autotelic provided an additional $120,000 short term loan to the company during the year ended December 31, 2022. During the six months ended June 30, 2023 Autotelic provided $680,000 in various short term loans to the Company. As such, $800,000 was outstanding and payable to Autotelic at June 30, 2023.

NOTE 6 - JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT

On March 31, 2022, the Company entered into (i) a joint venture (the “JV”) agreement with Dragon and GMP Bio, both affiliates of GMP, (and the Company, Dragon and GMP Bio are collectively called the “Parties”) (the “JVA”), (ii) a license agreement for rights to OT-101 (the “US License Agreement”) for the territory within the United States of America (the “US”) with Sapu Holdings, LLC, a subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio (the “Ex-US Rights Agreement”, and the US License Agreement and the Ex-US License Agreement are collectively called the “Agreements”). For more information on the JV, JVA, and Agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

As of the effective date of the formation of the JV, the combined enterprise value of GMP Bio was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million. As of June 30, 2023, the JV had approximately $22.7 million in assets, not including GMP Bio’s capital subscriptions of approximately $19 million; recorded approximately $0.5 million in liabilities and incurred approximately $1.5 million in operational expenses for the three months ended June 30, 2023, as GMP’s fiscal year commences on April 1 and ends on March 31. The Company elected the fair value option under subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that it the most appropriate method to properly value the Company and record a change in value when and upon conducting a fair value assessment. As of June 30, 2023, the Company does not believe the fair value of the JV has changed and hence has not recorded a change in value.

For information on the various notes from GMP, refer to Note 5 – GMP Notes of the Notes to the Consolidated Financial Statements above.

NOTE 7 - PRIVATE PLACEMENT AND JH DARBIE FINANCING

During the period from July 2020 to March 31, 2021, the Company entered into various subscription agreements with certain accredited investors, including the CEO, pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of 100 Units, for total gross proceeds of approximately $5 million, pursuant to the JH Darbie Placement Agreement, with each Unit consisting of:

	■	25,000 shares of Edge Point Common stock for a price of $1.00 per share of Edge Point Common stock.
	■	One convertible promissory note, convertible up to 25,000 shares of Edge Point Common stock, at a conversion price of $1.00 per share or up to 138,889 shares of the Company’s common stock, at a conversion price of $0.18 per share.
	■	50,000 warrants to purchase an equivalent number of shares of Edge Point Common stock at $1.00 per share and an equivalent number of shares of the Company’s common stock at $0.20 per share with a three-year expiration date. Either the Edgepoint or the Company’s warrants would be exercised.

As June 30, 2023 and December 31, 2022 funds received under the JH Darbie Financing, net of debt discount, consist of the following amounts:

	June 30, 2023		December 31, 2022
Convertible promissory notes
Subscription agreements - accredited investors	$	2,397,238	$	2,441,471
Subscription agreements – related party		125,000		124,547
Total convertible promissory notes	$	2,522,238	$	2,566,018

The Company incurred approximately $0.64 million of issuance costs, including legal costs of approximately $39,000, that are incremental costs directly related to the issuance of the various instruments bundled in the offering.

Concurrently with the sale of the Units, JH Darbie was granted a warrant, exercisable over a five-year period, to purchase 10% of the number of Units sold in the JH Darbie Financing. As such, the Company granted 10 Units to JH Darbie pursuant to the JH Darbie Placement Agreement.

The terms of convertible notes are summarized as follows:

	■	Term: Through March 31, 2022, extended further to March 31, 2023
	■	Coupon: 16%.
	■	Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock.
	■	The conversion price is initially set at $0.18 per share for the Company’s Common Stock or $1.00 for Edgepoint Common Stock, subject to adjustment.

For more information on the private placement, refer to our 2022 Annual Report on Form 10-K filed with the SEC on April 19, 2023.

In February 2022, the Company and all except one of the Investors agreed to extend the maturity date of the Notes from March 31, 2022, to March 31, 2023. In consideration for the extension of the Notes, the Company issued to the Investors an aggregate of 33,000,066 Oncotelic Warrants at a price of $0.15 per share of Company’s Common Stock. Each Investor will be entitled to receive 333,334 Oncotelic Warrants for each Unit purchased. Upon the amendment of the terms of the convertible notes under the private placement memorandum. As incentive to extend the maturity date, approximately 33 million warrants were issued to the Unit Holders who participated in the amendment, The Company repaid the 1-unit holder who did not participate in the amendment shortly after March 31, 2022. During the six months ended June 30, 2023, the Company partially repaid one unit holder,who will not be participating in the new JH Darbie financing.

The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $8,400 and approximately $52,000 for the six months ended June 30, 2023 and 2022, respectively, which is included in interest expense in the statements of operations.

As of June 30, 2023, the JH Darbie PPM Notes are in default as these notes were to be paid at the end of March 2023. The Company is in discussion with JH Darbie to close out these notes. The Company and JH Darbie have started a new private placement financing and which will be used, partially, to have the earlier PPM participants to roll over their investments into the new private placement. In this connection, 40 unit holders, comprising 15 investors, have already converted their notes into the new private placement after the close of this quarter. The Company is still working with the remaining prior JH Darbie financing investors to roll over their promissory notes into the new private placement. While the Company is fairly confident most, if not all the prior PPM investors, will roll over their debt into the new private placement.

NOTE 8 - RELATED PARTY TRANSACTIONS

Master Service Agreement with Autotelic Inc.

In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is partly-owned by the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The MSA stated that Autotelic Inc. will provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services.

Expenses related to the MSA were $0 for the three months ended June 30, 2023 as compared to approximately $1,000 for the same period of 2022.

License Agreement with Autotelic Inc.

In September 2021, the Company entered into an exclusive License Agreement with Autotelic. For more information on the exclusive license Agreement with Autotelic, refer to our 2022 Annual Report on Form 10-K filed with SEC on April 15, 2022.

Note Payable and Short-Term Loan – Related Parties

In April 2019, the Company issued a convertible note to Dr. Trieu totaling $164,444, including OID of $16,444, receiving net proceeds of $148,000, which was used by the Company for working capital and general corporate purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $250,000. Dr. Trieu also offset certain amounts due to him in the amount of $35,000 and was converted into the Fall 2019 debt. During the year ended December 31, 2020, Dr. Trieu provided additional short-term funding of $70,000 to the Company, of which the Company repaid $50,000 prior to December 31, 2020. During the year ended December 31, 2020, Dr. Trieu purchased a total of 5 Units under the private placement for a gross total of $250,000.

In May 2021, Autotelic provided an additional short-term funding of $250,000 to the Company, which was converted into the August 2021 Notes. Autotelic provided an additional $120,000 short term loan to the company during the year ended December 31, 2022. During the six months ended June 30, 2023 Autotelic provided $680,000 short term loan to the Company. As such, $800,000 was outstanding and payable to Autotelic at June 30, 2023.

Artius Consulting Agreement

On March 9, 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. King is the Managing Member, entered into an amendment to the Consulting Agreement dated December 1, 2018, under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time, effective December 1, 2019 (the “Effective Date”) (the “Artius Agreement”). For more information on this Agreement, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022.

No expense was recorded during the three and six months ended June 30, 2023 or 2022, respectively, related to this Agreement.

Maida Consulting Agreement

Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020 (the “Maida Agreement”), under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials. For more information on this Agreement, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022.

The Company recorded an expense of $0 during the six months ended June 30, 2023 related to this Agreement as compared to $75,000 during the same period in 2022. No similar expense was recorded during the three months of June 30, 2023 or 2022. Effective April 1, 2022, Dr Maida’s compensation shall be borne by the JVA with GMP Bio.

NOTE 9 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

In May 2021, the Company entered into an Equity Purchase Agreement (“EPL”) and Registration Rights Agreement with Peak One Opportunity Fund LP (“Peak One” or the “Investor”). For further information on EPL, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022.

The Company filed a post-effective amendment Registration Statement on Form S-1 with the Commission in April 2022, and the Form S-1 was declared effective in May 2022 and the Company filed the prospectus in this connection in May 2022. Further, the Company filed a second post-effective amendment Registration Statement on Form S-1 with the Commission in April 2023, and the Form S-1 was declared effective in April 2023. The Company filed the prospectus in this connection on May 2, 2023.

During the six months ended June 30, 2023, the Company did not sell any shares of Common Stock under the EPL.

During the six months ended June 30, 2022, the Company sold a total of 600,000 shares of Common Stock at price ranging from $0.16 and $0.22 for total gross proceeds of approximately $114,930 and approximately $98,627, net of issuance costs.

NOTE 10 - STOCKHOLDERS’ EQUITY

The following transactions affected the Company’s Stockholders’ Equity:

Issuance of Common Stock during the six months ended June 30, 2023

In February 2023, Blue Lake partially converted $71,750 of their debt. In connection with the partial Note conversion, the Company issued 1,025,000 shares of Common Stock to Blue Lake.

In June 2023, Blue Lake converted the full remainder of their $181,750 debt, accrued interest and penalty. In connection with this Note conversion, the Company issued 3,466,853 shares of Common Stock to Blue Lake.

In May and June 2023, Fourth Man converted $50,000 in principal and $30,000 in accrued interest into 1,192,857 shares of common stock.

Issuance of Common Stock during the six months ended June 30, 2022

In January 2022, three of the five investors from the November/December 2021 financing made a cashless exercise for their warrants. In connection with this exercise, the Company issued 3,041,958 shares of Common Stock in exchange of approximately 5,769,231 million warrants.

In March 2022, the Company sold 300,000 shares of its Common Stock to Peak One under the EPL for net proceeds of approximately $52 thousand.

In May 2022, Blue Lake made a cashless exercise for their warrants. In connection with this exercise, the Company issued 1,403,326 shares of Common Stock in exchange of 1,923,077 warrants.

In June 2022, the Company sold 300,000 shares of its Common Stock to Peak One under the EPL for net proceeds of approximately $47 thousand.

In June 2022, Mast Hill converted their debt of approximately $0.28 million. In connection with the Note conversion, the Company issued 4,025,000 shares of Common Stock to Mast Hill.

In June 2022, Company issued 500,000 shares of Common Stock to First Fire under partial repayment of convertible debt of $35,000.

In June 2022, First Fire made a cashless exercise for their warrants. In connection with this exercise, the Company issued 1,183,400 shares of Common Stock in exchange for 1,923,077 warrants.

For further information on Common Stock issuance, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022.

NOTE 11 – STOCK-BASED COMPENSATION

Options

Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details the Company’s associated option activity.

As of June 30, 2023, the Company had options to purchase Common Stock that were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). Under the 2017 Plan, up to 2,000,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to 27,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards

Employees, consultants, and directors are eligible for awards granted under the 2017 and 2015 Plans. Since the adoption of the 2015 Plan, no further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms.

Compensation based stock option activity for qualified and unqualified stock options are summarized as follows:

				Weighted
For the six months ended June 30, 2023				Average
	Shares			Exercise Price
Outstanding at January 1, 2023		25,690,261		$	0.23
Expired or cancelled		(1,512,500	)		0.46
Outstanding at June 30, 2023		24,177,761			0.21

				Weighted
For the six months ended June 30, 2022				Average
	Shares			Exercise Price
Outstanding at January 1, 2022		16,592,620		$	0.30
Expired or cancelled		(2,359	)		11.88
Outstanding at June 30, 2022		16,590,261		$	0.30

Information on compensation-based stock option activity for qualified and unqualified stock options for the year ended December 31, 2021 can be found in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 19, 2023.

The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at June 30, 2023:

				Weighted-		Weighted-
				Average		Average
		Outstanding		Remaining Life		Exercise		Number
Exercise prices		Options		In Years		Price		Exercisable

$	0.1 to 0.15		16,250,000		8.7	$	0.12		6,057,500
	0.16		5,502,761		8.0		0.16		5,502,761
	0.22		1,000,000		5.0		0.22		1,000,000
	0.38		550,000		3.5		0.38		550,000
	0.73		500,000		2.7		0.73		500,000
	1.43		300,000		1.9		1.43		300,000
	15.00		75,000		1.9		15.00		75,000
			25,690,261		8.0	$	0.21		13,985,261

The compensation expense attributed to the issuance of the options is recognized as they are vested. The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years.

As of June 30, 2023, there was no unamortized stock compensation cost related to the stock options granted during the year as the stock options granted during the year ended December 31, 2022 are considered vested. Of the approximately 14 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. For more information on the stock options, refer to our 2022 Annual Report on Form 10-K filed with the SEC on April 14, 203 or 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

The Company amortized $0 stock compensation expense during the six months ended June 30, 2023 on the 2021 and 2022 grants. The Company recorded $50,000 of similar expense during the same period of 2022.

Warrants

The Company has issued warrants in connection with the various financings conducted by the Company. For mor information on the warrant issuances, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 17, 2023. The Company issued 10,576,924 warrants related to the November/December 2021 Notes (See Note 6). The fair value of these warrants on issue date amounted to $1,172,753 as calculated using a Black Scholes valuation model.

The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of June 30, 2023 and 2022 are summarized as follows:

SCHEDULE OF WARRANTS ACTIVITY

For the three months ended June 30, 2023				Average
	Shares			Exercise Price
Outstanding at January 1, 2023		81,072,855		$	0.18
Issued during the six months ended June 30, 2023		-			-
Exercised / cancelled during the six months ended June 30, 2023		(42,737,500	)		0.2
Outstanding at June 30, 2023		38,335,355		$	0.16

For the six months ended June 30, 2022				Average
	Shares			Exercise Price
Outstanding at January 1, 2022		53,314,424		$	0.20
Issued during the six months ended June 30, 2022		34,375,066			0.15-0.20
Exercised / cancelled during the six months ended June 30, 2022		(9,615,385	)		0.13
Outstanding at June 30, 2022		82,322,855		$	0.18

The following table summarizes information about warrants outstanding and exercisable at June 30, 2023:

		Outstanding and exercisable
				Weighted-		Weighted-
				Average		Average
		Number		Remaining Life		Exercise		Number
Exercise Price		Outstanding		in Years		Price		Exercisable
$	0.13		961,539		3.46		0.13		961,539
	0.15		33,000,066		0.75		0.15		33,000,066
	0.20		4,373,750		3.75-3.98		0.20		4,373,750
			38,335,355		0.75	$	0.15		38,335,355

NOTE 12 – INCOME TAXES

The Company had gross deferred tax assets, which primarily relate to net operating loss carryforwards. As of December 31, 2021, the Company had gross federal and state net operating loss carryforwards, which are available to offset future taxable income, if any. The Company recorded a valuation allowance in the full amount of its net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. For information on our deferred tax assets and liabilities, refer to our 2022 Annual Report on Form 10-K filed with the SEC on April 14, 203 or 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

Portions of these carryforwards will expire through 2038, if not otherwise utilized. The Company’s utilization of net operating loss carryforwards could be subject to an annual limitation. as a result of certain past or future events, such as stock sales or other equity events constituting a “change in ownership” under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations could result in the expiration of net operating loss carryforwards and tax credits before they can be utilized. We have not performed a formal analysis, but we believe our ability to use such net operating losses and tax credit carryforwards will be subject to annual limitations, due to change of ownership control provisions under Section 382 and 383 of the Internal Revenue Code, which would significantly impact our ability to realize these deferred tax assets.

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Leases

Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations.

PointR Merger Contingent Consideration

The total purchase price in the PointR Merger of $17,831,427 represented the consideration transferred from the Company and was calculated based on the number of shares of Common Stock plus the preferred shares outstanding but convertible into Common Stock outstanding at the date of the PointR Merger and included $2,625,000 of contingent consideration of shares issuable to PointR shareholders, which could increase to $15 million of contingent consideration, upon achievement of certain milestones. For more information on the PointR Merger Contingent Consideration, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022.

Third Party Service Provider Claim

The Company is disputing a judgement of $20,000 for a non-payment to a third service provider. The Company considers the claim to be immaterial to the financial position of the Company. The Company has filed a counter claim on the third party service provider as the Company believes the claim to be false and malicious to the interests of the Company, and intends to vigorously defend the counter claim.

Other claims

From time to time, the Company may become involved in certain claims arising in the ordinary course of business. One of the Company’s ex-employees has made a claim against the Company. The Company is evaluating the validity of the claim, as the Company believes that such claim has limited merits and is hopeful to attain a positive outcome for such claim. Since the Company is still evaluating the claim, we are unable to quantify the amount such claim would be settled at, if at all settled.

NOTE 14 – SUBSEQUENT EVENTS

New Private Placement with JH Darbie

In July 2023, completed entering into subscription agreements with certain accredited investors (“Subscription Agreement”), whereby the Company issued a total of 40 units (“Units”), with each Unit consisting of (i) one convertible promissory note issued by the Company (the “Note”), convertible into up to 250,000 shares of 250,000 shares of the Company’s common stock, par value $0.01 per share (“the Company’s Common Stock”), at a conversion price of $0.10 per Company’s Common Stock; and (iii) 250,000 warrants (the “Warrants”) to purchase an equivalent number of shares of Company Common Stock at $0.12 per share (the “Financing”). The Company converted the debt of 15 accredited investors into the current Subscription Agreements, which resulted in conversion of $1.0 million of debt to the Company. These conversions were for the prior private placement by JH Darbie (See Note 7 of these Notes to Unaudited Financial Statement. Placement agent fees of $150,000 were paid to JH Darbie & Co., Inc. (“JH Darbie. JH Darbie and the Company are parties to a placement agent agreement, dated March 10, 2023 (“Agreement”) pursuant to which DH Darbie has the right to sell a minimum of 10 Units and a maximum of 200 Units on a best efforts basis.

Share Issuance

In July 2023, Fourth Man converted the final balance of approximately $44,000, inclusive of interest and penalty, of their December 2021 Note in exchange for 627,538 shares of our Common Stock.

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (the “Quarterly Report” or “Report”) includes a number of forward-looking statements that reflect management’s current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Some of these risks are included in the section entitled “Risk Factors” set forth in this Quarterly Report and in other reports that we file with the SEC. The occurrence of any of these risks, or others of which we are currently unaware, may cause our company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include, by way of example and without limitation:

●	our ability to successfully commercialize our products and services on a large enough scale to generate profitable operations;
●	our ability to maintain and develop relationships with customers and suppliers;
●	our ability to successfully integrate acquired businesses or new products, or to realize anticipated synergies in connection with acquisitions of businesses or products;
●	expectations concerning our ability to raise additional funding and to continue as a going concern;
●	our ability to successfully implement our business plan; and
●	our ability to avoid, or to adequately address any intellectual property claims brought by third parties; and
●	the anticipated impact of any changes in industry regulation.

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

Corporate History

Oncotelic Therapeutics, Inc. (also d/b/a Mateon Therapeutics, Inc.) (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, changed its name to Mateon Therapeutics, Inc. in 2016, and then Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation, Pet2DAO Inc., a Delaware corporation and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR and Edgepoint are collectively called the “Company”or “We”). The Company completed a reverse merger with Oncotelic Inc in April 2019, a merger with PointR in November 2019 and formed a subsidiary Edgepoint in February 2020. For more information on these mergers, refer to our 2020 Annual Report on Form 10-K filed with the SEC on April 15, 2021.

Company Overview

We are a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. Our goal is to advance our drug candidates into late-stage pivotal clinical trials and either sell marketing rights to a larger pharmaceutical company or seek FDA approval ourselves.

The Company is currently developing OT-101, through its joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), both affiliates of Golden Mountain Partners (“GMP”), for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for manufacturing, COVID-19 and other AI technologies. The Company is also independently planning to develop OT-101 for certain animal health indications and contemplating using crypto currencies for that platform. The Company has acquired apomorphine for Parkinson’s Disease, erectile dysfunction and female sexual dysfunction. In addition, the Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.

Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $4.5 million. $3.5 million of this amount was to fund the COVID-19 trial in Latin America and the rest was to debt to fund our operations till the culmination of the JV.

For more information on the GMP debt financing and the JV, refer to Notes 5 and 6 of the unaudited Notes to the Consolidated Financial Statements.

In November 2022, the Company formed a Decentralized autonomous organization (“DAO”) entity, Pet2DAO, Inc. (“Pet2DAO”), as a wholly owned subsidiary. A DAO is an emerging form of legal structure, that has no central governing body, and whose members share a common goal to act in the best interest of the entity. Pet2DAO is a DAO technology company, integrating the strong governance of traditional corporations with the innovative DAO architecture. The Company will look to engage stakeholders, to build value through the DAO, while maintaining the rigor of traditional corporations, including governance, compliance, and accountability through a team of veterans in public companies with innovators in AI, blockchain and Web3. Pet2DAO will initially be looking to develop products for the animal health space. The Company will initially issue regular tokens and non-fungible tokens (“NFT” and cumulatively “Tokens”) of Pet2DAO called PDAO to its employees, shareholders, and key opinion leaders (“KOLs’) and use the Tokens to propose and vote on various animal health related programs. In the future, the Company will evaluate and plan to register these tokens with the SEC to make such Tokens freely tradable at a future point in time.

Since April 2019, we have been operating under significant capital constraints, which has curtailed our ability to achieve meaningful progress in either of the Company’s two clinical programs – one of which is developing OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and the other of which is developing CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. We believe that the merger of Oncotelic and Oncotelic Inc. creates a combined company that has potential to generate shareholder value through a promising pipeline of next generation immunotherapies targeting several significant cancer markets where there is a lack of therapeutic options and lack of an effective immunotherapy protocol.

Research Service Agreement between and Financing between GMP and the Company

When COVID-19 emerged in China, the Company and GMP contemplated a collaboration to develop drug candidates for COVID-19.

In consideration for the financial support provided to GMP for the research, pursuant to the terms of the GMP Research Agreement (as amended by the GMP Research Supplement), GMP was entitled to obtain certain exclusive rights to the use of the GMP Agreement Product in the COVID Field on a global basis, and an economic interest in the use of the GMP Agreement Product in the COVID-19 Field including profit sharing to be decided. For more information on the collaborations with GMP, refer to our 20212 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. In March 2022, the Company entered into a JV transaction with Dragon to form GMP Bio, both entities being affiliates of GMP. Dragon and the Company will own in a / ratio, respectively, and its principal activities shall be to research, develop, bring to market and commercialize: (i) the GMP Agreement Products in the COVID-19 Field on a global basis, (ii) the GMP Agreement Products in the OT-101 Oncology Field in the territory set forth above, and if GMP so decides to include (iii) OXi4503 in the territory set forth above; and (iv) CA4P in the territory set forth above.

In June 2020, the Company secured a $2 million in debt financing, evidenced by a one-year secured convertible note from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19. For more information and terms on the Note, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 GMP has extended the maturity of the GMP Note to December 31, 2023, with no concessions granted to GMP for such extension. Such financing was utilized solely to fund the clinical trial. Similarly, in September 2021, the Company secured a further $1.5 million in debt financing

Between October 2021 and January 2022, the Company entered into two Unsecured Convertible Note Purchase Agreement with GMP, pursuant to which the Company raised a total of $1.0 million. The terms were the same as the June 2020 and September 2021 Notes. Such financings were utilized solely to fund the operations of the Company till the culmination of the JV.

For more information on the various notes with GMP, refer to Note 5 of this Quarterly Report.

Joint Venture

In March 2022, the Company entered into (i) a joint venture (the “JV”) agreement with Dragon and GMP Bio (and the Company, Dragon and GMP Bio are collectively called the “Parties”) (the “JVA”), (ii) a license agreement for rights to OT-101 (the “US License Agreement”) for the territory within the United States of America (the “US”) with Sapu Holdings, LLC, a subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio (the “Ex-US Rights Agreement”, and the US License Agreement and the Ex-US License Agreement are collectively called the “Agreements”). For more information on the development of Artemisinin, refer to our Annual Report on Form 10K filed with the SEC on April 14, 2023 or our Amended Annual Report on Form 10K/A filed with the SEC on April 19, 2023.

This JV is a significant milestone in the history of the Company as it permits the Company to monetize and develop the assets it holds, by minimal to no shareholder dilution. This transaction allows us to unburden the Company of the high cost of drug development, which the JV will be responsible for, while the Company will participate in its upside through appreciation in the value of its shares in the JV and up to $50 million on the sale of the RPD voucher following marketing approval of OT-101 for DIPG has agreed to invest cash and other assets with a value of approximately $27.6 million for 55% ownership of the JV; and Oncotelic had granted the License to the JV for 45% ownership in the JV for a fair value of about $22.6 million. The cash contributions by Dragon will allow the JV to commence the development of OT-101.

For information on the JV, refer to Note 6 – Joint Venture and GMP of the Notes to the Consolidated Financial Statements above.

New Private Placement with JH Darbie

For more information on the prior JH Darbie Financing, review Note 5 of this Quarterly Report.

August 2021 Notes

In August 2021, the Company entered into Note Purchase Agreements with Autotelic, the Company’s CFO, and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 (the “Principal Amount”) in debt in the form of unsecured convertible promissory notes (collectively, the “August 2021 Notes”). For more information on the August 2021 Notes, refer to Note 5 of this Quarterly Report.

November – December 2021 and March 2022 Financing

May 2022 Financing

In May 2022, the Company entered into a Securities Purchase Agreements with Mast, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.6 million, which Note is convertible into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). This note was used to fully repay November 2021 Talos note and the December 2021 First Fire note. For more information on the May 2022 Financing, refer to Note 5 of this Quarterly Report.

June 2022 Financing

In June 2022, the Company entered into a Securities Purchase Agreements with Blue Lake, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.34 million, which Note is convertible into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). This note was utilized for corporate expenses. For more information on the June 2022 Financing, refer to Note 5 of this Quarterly Report.

Short-term loans

During the year ended December 31, 2021, the Company’s CFO, a related Party, provided short term advances of approximately $45,000. $20,000 was repaid to the CFO in January 2022. In the six months ended June 30, 2023, the company’s CFO provided additional short-term advance of $10,000. As such approximately $35,000 was outstanding at June 30, 2023.

Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expense during the reporting periods. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time we make such estimates. Actual results and outcomes may differ materially from our estimates, judgments and assumptions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate. Our significant accounting policies are more fully described in Note 2 to our Unaudited Consolidated Financial Statements included elsewhere in this Quarterly Report.

We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. We believe the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments are the following:

Impairment of Long-Lived Assets

The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the six months ended June 30, 2022 and 2021, there were no impairment losses recognized for long-lived assets.

Intangible Assets

Goodwill

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

Derivative Financial Instruments Indexed to the Company’s Common Stock

Variable Interest Entity (VIE) Accounting

We evaluate our ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements.

Investments - Equity Method

The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares are included in the result from continuing operations. Refer to Note 6 to these Notes to the Consolidated Financial Statements.

Joint Venture agreement

We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (CDMO) facilities and capabilities. The Company first review the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture

The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment.

Research and Development Expense

Research and development expense consist of costs we incur for the development of our investigational drugs and, to a lesser extent, for preclinical research activities. Research and development costs are expensed as incurred. Research and development expense include clinical trial costs, salaries and benefits of employees, including associated stock-based compensation, payments to clinical investigators, drug manufacturing costs, laboratory supplies and facility costs. Clinical trial costs are a significant component of our research and development expense, and these can be difficult to accurately estimate. Included in clinical trial costs are fees paid to other entities that conduct certain research and development activities on our behalf, such as clinical research organizations, or CROs. We estimate clinical trial expense based on the services performed pursuant to contracts with research institutions such as CROs and the actual clinical investigators. These estimates are based on actual time and expenses incurred by the CRO and the clinical investigators. Also included in clinical trial expense are costs based on the level of patient enrollment into the clinical trial and the actual services performed under the related clinical trial agreement. Changes in clinical trial assumptions, such as the length of time estimated to enroll all patients, rate of screening failures, patient drop-out rates, number and nature of adverse event reports and the total number of patients enrolled can impact the average and expected cost per patient and the overall cost of the clinical trial. Based on patient enrollment reports and services provided, we may periodically adjust estimates for the clinical trial costs. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed, the length of time for these services or the costs of these services, our actual expenses could differ from our estimates.

Share-Based Compensation

We record the estimated fair value of all share-based payments issued to employees and other service providers. Our share-based payments consist primarily of stock options. The valuation of stock options is an inherently subjective process, since market values are not available for any stock options in our equity securities. Market values are also not available on long-term, non-transferable stock options in other equity securities. With no market values on options to trade in our common stock and no comparable market values on any long-term non-transferable stock options, the process of valuing our stock options is even more uncertain and subjective. Accordingly, we use a Black-Scholes option pricing model to derive an estimated fair value of the stock options which we issue. The Black-Scholes option pricing model requires certain input assumptions, including the expected term of the options and the expected volatility of our common stock. Changes in these assumptions could have a material impact on the estimated fair value that we record for share-based payments that we issue. We determine the term of the options based on the simplified method, which averages the vesting period and the contractual life of the stock option. We determine the expected volatility based on the historical volatility of our common stock over a period commensurate with the option’s expected term. The Black-Scholes option pricing model also requires assumptions for risk-free interest rates and the expected dividend yield of our common stock, but we feel that these values are more objective and note that changes in these values do not have a significant impact on the estimated value of the options when compared to the volatility and term assumptions.

We are also required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. Accordingly, we perform a historical analysis of option awards that are forfeited prior to vesting, and record total stock option expense that reflects this estimated forfeiture rate.

Results of Operations

Comparison of the Results of Operations for the three Months Ended June 30, 2023 to the three Months Ended June, 2022

A comparison of the Company’s operating results for the three months ended June 30, 2023 and 2022, respectively, is as follows.

	June 30, 2023			June 30, 2022			Variance
Operating expense:
Research and development		-			108,707			(108,707	)
General and administrative		238,758			147,608			91,150
Goodwill impairment		6,083,146			-			6,083,146
Total operating expense		6,321,904			256,315			6,065,589	)
Loss from operations		(6,321,904	)		(256,315	)		(6,065,589	)
Reimbursement for expenses – related party		-			247,492			(247,492	)
Interest expense, net		(257,396	)		(1,094,878	)		837,482
Gain on derecognition of non-financial asset		-			16,951,477			(16,951,477	)
Change in the value of derivatives on debt		(307,698	)		122,919			(430,617	)
Miscellaneous income		36,988			-			36,988
Net income (loss) before controlling interests	$	(6,850,010	)	$	15,970,695		$	(22,820,705	)

Net Income (Loss)

We recorded a net loss of approximately $6.8 million for the three months ended June 30, 2023, as compared to net income of approximately $16.0 million for the three months ended June 30, 2022. The difference in net income (loss), of approximately $22.8 million, between the three months ended June 30, 2023 as compared to the same period of 2022 was primarily due to gain on derecognition of non-financial asset of approximately $17 million, reduced by higher impairment to goodwill of $6.1 million during the six months ended June 30, 2023;lower change in value of derivatives on debt of approximately $0.4 million, for the three months ended June 30, 2022 and offset by lower interest of approximately $0.8 million, for the three months ended June 30, 2023.,

Research and Development Expenses

Research and development (“R&D”) expenses decreased by approximately $0.1 million for the three months ended June 30, 2023 compared to the same period in 2022, primarily due to lower personnel expenses and other operational expenses relate to OT-101 being borne by the JV and reversal of over accrual of certain R&D expenses.

As previously disclosed, and as a result of our JV, we expect our R&D expense to decrease for the remainder of the year 2023, specifically for activities related to OT-101, including the initiation of new clinical trials. Any other development expenses will be subject to our continuing ability to secure sufficient funding to continue planned operations.

General and Administrative Expenses

General and administrative (“G&A”) expenses increased by approximately $0.1 million for the three months ended June 30, 2023 compared to the three months ended June 30, 2022, primarily due to higher legal and professional expenses.

As previously disclosed and as a result of our JV, we expect our G&A activities to remain steady or marginally increase for the remainder of 2023. Any other G&A expenses will be subject to our continuing ability to secure sufficient funding to continue planned operations.

Goodwill Impairment

We recorded a goodwill impairment of approximately $6.1 million on the approximately $12 million goodwill, which we recorded upon our acquisition of PointR, for the three months ended June 30, 2023. No similar impairment was recorded for the same period of 2022.

During the second quarter of 2023, we observed a significant decline of our stock price, the market capitalization of our Company, and the general economic conditions, which adversely impacted the majority of the pharmaceutical and biotechnology industry. These were indicative of a potential impairment of our goodwill. While we evaluated and concluded that the AI technologies related to the PointR acquisition are not adversely impacted as the Company continues to develop other AI technologies, the significant reduction of our market capitalization required us to record an impairment on the goodwill to the extent of the difference between the net assets of the Company over the fair value, solely based on the market capitalization.

Reimbursement of expenses

The Company was reimbursed approximately $0.25 million, by Autotelic Inc. a related party, during the three months ended June 30, 2022 on behalf of our JV. No similar expenses were reimbursed during the three months ended June 30, 2023.

Interest Expense, Net

We recorded interest expense, including amortization of debt costs, of approximately $0.3 million for the three months ended June 30, 2023 as compared to approximately $1.1 million for the three months ended June 30, 2022 primarily in connection with debt raised from convertible notes and the JH Darbie Financing, November/December 2021 Financing and May/June 2022 financing as compared to $0.4 million for the same period of 2021, in connection with debt raised from convertible notes and JH Darbie during 2021. Interest expense was lower for the three months ended June 30, 2023 as compared to the same period of 2022 due to lower the adoption of ASU 2020-06 effective from January 1, 2023 and significantly reduced amortization beneficial conversion feature (“BCF”) interest components. For more information on debt raised from convertible notes and the JH Darbie Financing, see Note 5 and Note 7 of the Unaudited Consolidated Financial Statements of this Quarterly Report.

Gain on Derecognition of Non-financial Asset

During the three months ended June 30, 2022, we recorded a gain of approximately $16.9 million on the sale of our non-financial asset upon the transfer of OT-101 as our capital contribution for the JV. We adopted the fair value measurements under the equity method and the gain was net of the fair value of the asset of approximately $22.6 million as reduced by the removal of the value of the intangibles of approximately $0.8 million for OT-101 and the value of the goodwill of $4.8 million recorded at the time of the 2019 Merger with Oncotelic Inc. No similar gain has been recorded during the three months ended June 30, 2023.

Change in Value of Derivatives

During the three months ended June, 2023, we recorded approximately $0.3 million change in value upon conversion of certain debt owed on the convertible promissory notes issued to our CEO and a bridge investor (collectively, the “Convertible Notes”). The Company recorded approximately $0.1 million change during the same period in 2021. The Convertible Notes became convertible 180 days after issuance, and as such the CEO and the bridge investor had the ability to convert that debt into equity at a variable conversion price, giving rise to a derivative feature within the debt instrument resulting in the recording of a derivative liability and change in value of the derivative. For more information on value of derivatives, refer to the Note 5 of the Unaudited Consolidated Financial Statements of this Quarterly Report.

Comparison of the Results of Operations for the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022

A comparison of the Company’s operating results for the six months ended June 30, 2023 and 2022, respectively, is as follows.

	June 30, 2023			June 30, 2022			Variance
Operating expense:
Research and development		28,927			689,004			(660,077	)
General and administrative		436,958			3,911,518			(3,474,560	)
Goodwill impairment		6,083,146			-			6,083,146
Total operating expense		6,549,031			4,600,522			1,948,509
Loss from operations		(6,549,031	)		(4,600,522	)		(1,948,509	)
Reimbursement for expenses – related party		72,246			247,492			(175,246	)
Interest expense, net		(651,675	)		(1,392,341	)		740,666
Gain on derecognition of non-financial asset		-			16,951,477			(16,951,477	)
Change in the value of derivatives on debt		(327,594	)		(67,922	)		(259,672	)
Loss on conversion of debt		-			(257,810	)		257,810

Net income (loss) before controlling interests	$	(7,456,054	)	$	10,880,374		$	(18,336,428	)

Net Income

We recorded a net loss of approximately $7.4 million for the six months ended June 30, 2023 as compared to a net income of approximately $10.9 million for the six months ended June 30, 2022. The difference in net income (loss), of approximately $18.3 million, for the six months ended June, 2023 as compared to the same period of 2022, was primarily due to recording a gain on the sale of non-financial asset of approximately $17 million during the three months ended June 30, 2022, lower operating expense of approximately $4.1 million, reduced by higher impairment losses of approximately $6.1 million, lower reimbursement of expenses by a related party of approximately $0.2 million, lower interest cost of approximately $0.7 million, higher change in value of derivatives on debt of approximately $0.3 million and lower loss on conversion of debt of approximately $0.3 million

Research and Development Expenses

Research and development (“R&D”) expenses decreased by approximately $0.7 million for the six months ended June 30, 2023 compared to the same period in 2022, primarily due to reduced compensation and operational costs of approximately $0.6 million and reduced clinical trial cost of $0.1 million. As a result of our JV with Dragon and GMP Bio, the JV absorbed most of the compensation costs as well as some of the operational costs.

As a result of our JV, we expect our R&D expense to decrease for the remainder of the year 2023, specifically for activities related to OT-101, including the initiation of new clinical trials. Any other development expenses will be subject to our continuing ability to secure sufficient funding to continue planned operations.

General and Administrative Expenses

General and administrative (“G&A”) expenses decreased by approximately $3.5 million for the six months ended June 30, 2023 compared to the six months ended June 30, 2022, primarily due to the lower stock based compensation of approximately $2.9 million, lower compensation costs of approximately $0.6 million, offset by lower legal and professional and operational costs of approximately $0.1 million.

As a result of our JV, we expect our G&A activities to remain steady or marginally increase for the remainder of 2023. Any other G&A expenses will be subject to our continuing ability to secure sufficient funding to continue planned operations.

Goodwill Impairment

We recorded a goodwill impairment of approximately $6.1 million on the approximately $12 million goodwill, which we recorded upon our acquisition of PointR, for the six months ended June 30, 2023. No similar impairment was recorded for the same period of 2022.

Interest Expense, Net

We recorded interest expense, including amortization of debt costs, of approximately $0.7 million for the six months ended June 30, 2023 as compared to $1.4 million for the six months ended June 30, 2022 primarily in connection with debt raised from convertible notes, JH Darbie Financing, November/December 2021 Financing and May/June 2022 Financing. Interest expense was lower for the three months ended June 30, 2023 as compared to the same period of 2022 due to lower the adoption of ASU 2020-06 effective from January 1, 2023 and significantly reduced amortization beneficial conversion feature (“BCF”) interest components. For more information on debt raised from convertible notes and the JH Darbie Financing, see Note 5 and Note 7 of the Unaudited Consolidated Financial Statements of this Quarterly Report.

Reimbursement of expenses

The Company was reimbursed approximately $0.1 million during the six months ended June 30, 2023 as compared to approximately $0.25 million, by Autotelic Inc. a related party, on behalf of our JV.

Gain on Derecognition of Non-financial Asset

During the three months ended June 30, 2022, we recorded a gain of approximately $16.9 million on the sale of our non-financial asset upon the transfer of OT-101 as our capital contribution for the JV. We adopted the fair value measurements under the equity method and the gain was net of the fair value of the asset of approximately $22.6 million as reduced by the removal of the value of the intangibles of approximately $0.8 million for OT-101 and the value of the goodwill of $4.9 million recorded at the time of the 2019 Merger with Oncotelic Inc. No similar gain has been recorded during the six months ended June 30, 2023.

Change in Value of Derivatives

During the six months ended June 30, 2023, we recorded approximately $0.3 million change in value upon conversion of the debt to liabilities as a derivative as well as new debt converting to liabilities on the Convertible Notes as compared to approximately $68 thousand change during the same period of 2022. The Convertible Notes became convertible 180 days after issuance, and as such Peak One, TFK, the CEO and the bridge investor had the ability to convert that debt into equity at: (i) the variable conversion price of 65% of the Company’s lowest traded price after the first 180 days, or (ii) at the lower of $0.10 per share or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument which resulted in the recording of a derivative liability and change in value of the derivative.

Loss on Conversion of Debt

During the six months ended June 30, 2022, we recorded a loss of $0.25 million on conversion of debt. related to the difference in fair value to the price at which the debt was converted. No similar expense was recorded during the six months ended June 30, 2023.

Liquidity, Financial Condition and Capital Resources ($s in ‘000’s)

	*June 30, 2023*			*December 31, 2022*
Cash, including restricted cash of $20	$	202		$	261
Working capital		(17,805	)		(16,620	)
Stockholders’ Equity		11,926			19,193

The Company has incurred net accumulated losses of approximately $32.9 million, negative working capital of over $17.8 million and negative cash flow from operations of approximately $0.7 million at June 30, 2023. Management expects to incur significantly lower costs losses in the foreseeable future and recognizes the need to raise capital to remain viable. The Company’s limited capital resources, history of recurring losses and uncertainties as to whether the Company’s operations will become profitable raise substantial doubt about its ability to continue as a going concern. The financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The principal source of the Company’s working capital deficit to date has been the issuance of convertible notes, a substantial part of which has been provided by officers and certain insiders, and sale of equity under the EPA with Peak One. The Company will need to raise additional capital in order to fund its operations and continue development of product candidates. The Company is evaluating the options to further the development of the Company’s product candidates, AL-101, Artemisinin for COVID-19, developing AI technologies to support the COVID-19 therapies; in addition to evaluating the development pathway of its product candidates; OXi4503 and/or CA4P.

The Company anticipates raising substantial additional capital through the sale of equity securities and/or debt, but no other financing arrangements are in place at this time.

If the Company is unable to access additional funds when needed, it may not be able to continue the development of these investigational drugs and the Company could be required to delay, scale back or eliminate some or all of its development programs and operations. Any additional equity financing, if available, would be dilutive to the current stockholders and may not be available on favorable terms. Additional debt financing, if available, may involve restrictive covenants and could also be dilutive. The Company’s ability to access capital is not assured and, if access is not achieved on a timely basis, would materially harm the Company’s financial condition, the value of its Common Stock and its business prospects.

Cash Flows ($ in ‘000’s)

	Six month ended June 30,
	2023			2022
Net cash used in operating activities	$	(700	)	$	(1,166	)
Net cash provided by financing activities		640			997
Increase (decrease) in cash	$	(60	)	$	(169	)

Operating Activities

Net cash used in operating activities was approximately $0.7 million for the six months ended June 30, 2022. This was due to the net loss of approximately $7.4 million, and primarily offset by approximately $6.1 million of goodwill impairment, approximately $0.3 million of change in fair value of derivative, approximately $0.3 million due to amortization of debt discounts and deferred financing costs and changes in operating assets and liabilities of approximately $0.1 million.

Financing Activities

For the six months ended June 30,2023, net cash provided by financing activities was approximately $0.6 million, due to a receipt of cash from short term loan from a related party of approximately $0.7 million offset by repayments of debt of approximately $50 thousand to one JH Darbie Financing note holder.

For the six months ended June 30,2022, net cash provided by financing activities was approximately $1.0 million, due to a receipt of cash from sale of shares under the EPA of approximately $0.1 million, a short-term convertible loan GMP of $0.5 million, approximately $1.0 million under the March 2022, May 2022 and June 2022 notes, offset by repayments of debt of approximately $0.5 million to some note holders and approximately $0.1 million to short term loan holders and one PPM note holder.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Effects of Inflation

We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

Contractual Obligations

Our current drug development programs are based on a series of compounds called combretastatins, which we have exclusively licensed from Arizona State University, or ASU. If our current drug candidates are approved, we will be required to pay low to mid-single-digit royalties on future net sales of products associated with the ASU patent rights until these patent rights expire.

We also have an exclusive license from Bristol-Myers Squibb, or BMS, for certain patent rights to particular combretastatins, including CA4P. If CA4P is approved, we will be required to pay low-single-digit royalties on future net sales of products associated with the BMS patent rights until these patent rights expire.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our cash is maintained in U.S. dollar accounts. We have adopted a policy for the cash that we hold, and also for any cash equivalents and investments that we may hold, the primary objective of which is to preserve principal, while also maintaining liquidity to meet our operating needs and maximize yields to the extent possible. Although our investments can be subject to credit risk, we follow procedures to limit the amount of credit exposure in any single issue, issuer or type of investment. Our investments are also subject to interest rate risk and would be likely to decrease in value if market interest rates increase. However, due to the generally conservative nature of our investments and relatively short duration, we believe that interest rate risk is mitigated.

Although we may from time-to-time manufacture drugs and conduct preclinical or clinical trials outside of the United States, we believe our exposure to foreign currency risk to be immaterial.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our CEO and our CFO each concluded that our disclosure controls and procedures are not effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) is accumulated and communicated to our management, including our CEO and our CFO, as appropriate to allow timely decisions regarding required disclosure.

Material Weaknesses in Internal Control over Financial Reporting

Management conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2023 based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Registrant’s internal control over financial reporting as of June 30, 2023 was not effective as a result of certain material weaknesses.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which are observed in many small companies with a small number of accounting and financial reporting staff:

●	Lack of formal policies and procedures;
●	Lack of a functioning audit committee and independent directors on the Company’s board of directors to oversee financial reporting responsibilities;
●	Inadequate or lack of segregation of duties;
●	Lack of dedicated resources and experienced personnel to design and implement internal control procedures to support financial reporting objectives;
●	Lack of qualified accounting personnel to prepare and report financial information in accordance with GAAP; and
●	Lack of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner.

Management’s Plan to Remediate the Material Weaknesses

Management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions planned include:

●	Continue to search for, evaluate and recruit qualified independent outside directors;
●	Hire qualified accounting personnel to prepare and report financial information in accordance with GAAP;
●	Identify gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company; and
●	Continue to develop policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

Changes in Internal Control over Financial Reporting

During the six months ended June 30, 2023, we continued to execute upon our planned remediation actions which are all intended to strengthen our overall control environment. While we have made progress in our planned remediation efforts and we expect the Company to complete its planned execution of internal controls over financial reporting during the year ended December 31, 2023, however, our ability to do so would greatly depend on our ability to obtain financial and other resources to complete the remediation.

We are committed to maintaining a strong internal control environment and believe that these remediation efforts will represent significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Please see the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2022 filed on April 14, 2023 or the Amended Annual Report on Form 10K/A filed on April 19, 2023 with the SEC. The risks described below and in our Form 10-K or Form 10K/A are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use Of Proceeds

In February 2023, Blue Lake partially converted $71,750 of their debt. In connection with the partial Note conversion, the Company issued 1,025,000 shares of Common Stock to Blue Lake.

In June 2023, Blue Lake the converted the full remainder of their $181,750 debt, accrued interest and penalty. In connection with this Note conversion, the Company issued 3,466,853 shares of Common Stock to Blue Lake.

In May and June 2023, Fourth Man converted $50,000 in principal and $30,000 in accrued interest into 1,192,857 shares of Common Stock.

In July 2023, Fourth Man converted $25,000 in principal, $17,178 in accrued interest and $1,750 of legal fees into 627,538 shares of Common Stock.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

ITEM 6. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

In reviewing the agreements included as exhibits to this Quarterly Report, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

	●	should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

	●	have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

	●	may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

	●	were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Quarterly Report and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

The following exhibits are included as part of this Quarterly Report and is not a complete list of all relevant and material agreements. A more complete list of previously filed Exhibits can be found with our Annual Report on Form 10K, or Amended Annual Report on Form 10K/A, filed with the SEC on April 14, 2023 and April 19, 2023, respectively:

		Incorporated by Reference
Exhibit Number	Description	Form	Filing Date	Exhibit Number	Filed Herewith

10.1	Amendment to the Oncotelic Therapeutics, Inc. 2015 Equity Incentive Plan	S-8	4/19/2021	10.1

10.2	Equity Purchase Agreement by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2021	8-K	5/7/2021	10.1

10.3	Registration Rights Agreement, by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2020	8-K	5/7/2021	10.2

10.4	Joint Venture Agreement relating to GMP Biotechnology Limited between Dragon Overseas Capital Limited, Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31, 2022	8-K	4/6/2022	10.1

10.5	License Agreement between Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31, 2022	8-K	4/6/2022	10.2

10.6	License Agreement between Oncotelic Therapeutics, Inc. and Sapu Holdings, LLC dated March 31, 2022	8-K	4/6/2022	10.3

10.7	Independent consulting agreement between Oncotelic Therapeutics, Inc. and Fatih Uckun, MD, Ph.D. dated May 1, 2022	8-K	5/6/2022	10.1

10.8	Independent consulting agreement between Oncotelic Therapeutics, Inc. and Seymour Fein, MD dated May 1, 2022	8-K	5/6/2022	10.2

10.9	Securities Purchase Agreement between Oncotelic Therapeutics Inc. and certain accredited investors dated May 27, 2022	8-K	6/3/2022	10.1

10.10	Securities Purchase Agreement between Oncotelic Therapeutics Inc. and certain accredited investors dated June 22, 2022	8-K	6/27/2022	10.1

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a).				x

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a).				x

32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				x

32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				x

101.1	Interactive Data Files for the Three and Six months ended June 20, 2023 and June 30, 2022				x

101.INS	Inline XBRL Instance Document				x

101.SCH	Inline XBRL Taxonomy Extension Schema				x

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase				x

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase				x

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase				x

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase				x

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				x

*	Confidential treatment has been granted for portions of this Exhibit. Redacted portions filed separately with the Securities and Exchange Commission.

+	Management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ONCOTELIC THERPAEUTICS INC.

By:	/s/ Vuong Trieu
	Vuong Trieu, Ph.D.
	Chief Executive Officer and Director (Principal Executive Officer)

Date:	August 18, 2023

By:	/s/ Amit Shah
	Amit Shah
	Chief Financial Officer (Principal Financial and Accounting Officer)

Date:	August 18, 2023

Exhibit 31.1

ONCOTELIC THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Vuong Trieu, Ph.D., certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of Oncotelic Therapeutics, Inc. for the period ended June 30, 2023;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Vuong Trieu
	Vuong Trieu, Ph.D.
	Chief Executive Officer (Principal Executive Officer)

Date:	August 18, 2023

Exhibit 31.2

ONCOTELIC THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Amit Shah, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q of Oncotelic Therapeutics, Inc. for the period ended June 30, 2023;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Amit Shah
	Amit Shah
	Chief Financial Officer (Principal Financial and Accounting Officer)

Date:	August 18, 2023

Exhibit 32.1

ONCOTELIC THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Oncotelic Therapeutics, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

By:	/s/ Vuong Trieu
	Vuong Trieu, Ph.D.
	Chief Executive Officer (Principal Executive Officer)

Date:	August 18, 2023

Exhibit 32.2

ONCOTELIC THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

By:	/s/ Amit Shah
	Amit Shah
	Chief Financial Officer (Principal Financial and Accounting Officer)

Date:	August 18, 2023

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 11, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-21990
Entity Registrant Name	Oncotelic Therapeutics, Inc.
Entity Central Index Key	0000908259
Entity Tax Identification Number	13-3679168
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	29397 Agoura Road
Entity Address, Address Line Two	Suite 107
Entity Address, City or Town	Agoura Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91301
City Area Code	(650)
Local Phone Number	635-7000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		398,159,128

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 181,872	$ 241,452
Restricted cash	20,000	20,000
Accounts receivable	18,976	19,748
Prepaid & other current assets	60,736	21,964
Total current assets	281,584	303,164
In process R&D	1,101,760	1,101,760
Goodwill, net of impairment	5,988,230	12,071,376
Investment in GMP Bio at fair value	22,640,519	22,640,519
Total assets	30,012,093	36,116,819
Current liabilities:
Accounts payable and accrued liabilities	2,458,589	2,510,864
Contingent consideration	2,625,000	2,625,000
Derivative liability on notes	525,734	198,140
Total current liabilities	18,086,145	16,923,407
Stockholders’ equity:
Common stock, $.01 par value; 750,000,000 shares authorized; 397,531,590 and 391,846,880 issued and outstanding, respectively	3,975,316	3,918,469
Additional paid-in capital	41,235,949	41,416,632
Accumulated deficit	(32,896,062)	(25,926,069)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	12,315,203	19,409,032
Non-controlling interests	(389,255)	(215,620)
Total stockholders’ equity	11,925,948	19,193,412
Total liabilities and stockholders’ equity	30,012,093	36,116,819
Related Party [Member]
Current liabilities:
Accounts payable to related party	343,001	332,432
Convertible debt and short-term debt - related party, net of costs	1,871,930	1,165,048
Nonrelated Party [Member]
Current liabilities:
Convertible debt and short-term debt - related party, net of costs	$ 10,261,891	$ 10,091,923

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	397,531,590	391,846,880
Common stock, shares outstanding	397,531,590	391,846,880

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development		$ 108,707	$ 28,927	$ 689,004
General and administrative	238,758	147,608	436,958	3,911,518
Goodwill impairment	6,083,146	(0)	6,083,146	(0)
Total operating expenses	6,321,904	256,315	6,549,031	4,600,522
Loss from operations	(6,321,904)	(256,315)	(6,549,031)	(4,600,522)
Other income (expense):
Reimbursement for expenses - related party		247,492	72,246	247,492
Interest expense, net	(257,396)	(1,094,878)	(651,675)	(1,392,341)
Gain on derecognition of non-financial asset		16,951,477		16,951,477
Change in fair value of derivative on debt	(307,698)	122,919	(327,594)	(67,922)
Miscellaneous income	36,988
Loss on extinguishment / conversion of debt				(257,810)
Total other income (expense)	(528,106)	16,227,010	(907,023)	15,480,896
Net income (loss) before non-controlling interests	(6,850,010)	15,970,695	(7,456,054)	10,880,374
Net loss attributable to non-controlling interests	(93,010)	(41,424)	(173,635)	(281,964)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$ (6,757,000)	$ 16,012,119	$ (7,282,419)	$ 11,162,338
Basic net income (loss) per share attributable to common stock	$ (0.02)	$ 0.04	$ (0.02)	$ 0.03
Basic weighted average common stock outstanding	394,374,227	379,203,841	393,829,610	378,588,600

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 3,752,881	$ 35,223,842	$ (31,021,050)	$ 202,758	$ 8,158,431
Balance, shares at Dec. 31, 2021	375,288,146
Net income (loss)			(4,849,781)	(240,540)	(5,090,321)
Common shares issued upon cashless exercise of warrants	$ 30,420	(30,420)
Common shares issued upon cashless exercise of warrants, shares	3,041,958
Common shares issued for cash	$ 3,000	48,805			51,805
Common shares issued for cash, shares	300,000
Stock compensation expense		297,360			297,360
Warrants issued in connection with debt issuance		2,905,316			2,905,316
Balance at Mar. 31, 2022	$ 3,786,301	38,444,903	(35,870,831)	(37,782)	6,322,591
Balance, shares at Mar. 31, 2022	378,630,104
Balance at Dec. 31, 2021	$ 3,752,881	35,223,842	(31,021,050)	202,758	8,158,431
Balance, shares at Dec. 31, 2021	375,288,146
Net income (loss)					10,880,374
Balance at Jun. 30, 2022	$ 3,860,418	40,357,610	(19,858,712)	(79,206)	24,280,110
Balance, shares at Jun. 30, 2022	386,041,862
Balance at Mar. 31, 2022	$ 3,786,301	38,444,903	(35,870,831)	(37,782)	6,322,591
Balance, shares at Mar. 31, 2022	378,630,104
Common shares issued in connection with debt conversion	$ 45,250	286,001			331,251
Common shares issued in connection with debt conversion, shares	4,525,000
Net income (loss)			16,012,119	(41,424)	15,970,695
Common shares issued upon cashless exercise of warrants	$ 25,867	(25,867)
Common shares issued upon cashless exercise of warrants, shares	2,586,758
Common shares issued for cash	$ 3,000	43,822			46,822
Common shares issued for cash, shares	300,000
Stock compensation expense		25,196			25,196
Warrants issued in connection with debt issuance		368,375			368,375
Beneficial Conversion Feature on convertible debt		570,717			570,717
Contribution from shareholder for payment of liabilities		644,463			644,463
Balance at Jun. 30, 2022	$ 3,860,418	40,357,610	(19,858,712)	(79,206)	24,280,110
Balance, shares at Jun. 30, 2022	386,041,862
Balance at Dec. 31, 2022	$ 3,918,469	41,416,632	(25,926,069)	(215,620)	19,193,412
Balance, shares at Dec. 31, 2022	391,846,880
Adoption of ASU 2020-06		(521,749)	312,426		(209,323)
Common shares issued in connection with debt conversion	$ 10,250	61,499			71,749
Common shares issued in connection with debt conversion, shares	1,025,000
Net income (loss)			(525,419)	(80,625)	(606,044)
Balance at Mar. 31, 2023	$ 3,928,719	40,956,382	(26,139,062)	(296,245)	18,449,794
Balance, shares at Mar. 31, 2023	392,871,880
Balance at Dec. 31, 2022	$ 3,918,469	41,416,632	(25,926,069)	(215,620)	19,193,412
Balance, shares at Dec. 31, 2022	391,846,880
Net income (loss)					(7,456,054)
Balance at Jun. 30, 2023	$ 3,975,316	41,235,949	(32,896,062)	(389,255)	11,925,948
Balance, shares at Jun. 30, 2023	397,531,590
Balance at Mar. 31, 2023	$ 3,928,719	40,956,382	(26,139,062)	(296,245)	18,449,794
Balance, shares at Mar. 31, 2023	392,871,880
Common shares issued in connection with debt conversion	$ 46,597	279,567			326,164
Common shares issued in connection with debt conversion, shares	4,659,710
Net income (loss)			(6,757,000)	(93,010)	(6,850,010)
Balance at Jun. 30, 2023	$ 3,975,316	$ 41,235,949	$ (32,896,062)	$ (389,255)	$ 11,925,948
Balance, shares at Jun. 30, 2023	397,531,590

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net profit	$ (6,850,010)	$ (606,044)	$ 15,970,695	$ (5,090,321)	$ (7,456,054)	$ 10,880,374
Adjustments to reconcile net profit to net cash provided by (used in) operating activities:
Gain on derecognition of non-financial asset			(16,951,477)			(16,951,477)
Goodwill impairment	6,083,146		(0)		6,083,146	(0)	$ 4,111,079
Amortization of debt discount and deferred finance costs					251,782	1,133,270
Amortization of intangible assets						12,841
Warrants issued in connection with private placement						2,905,316
Stock-based compensation						322,556
Change in fair value of derivative	307,698		(122,919)		327,594	67,922
Loss on debt conversion						257,810
Changes in operating assets and liabilities:
Prepaid expenses and other current assets					(38,000)	(4,932)
Accounts payable and accrued expenses					117,289	276,704
Accounts payable to related party					14,663	(66,183)
Net cash provided by (used in) operating activities					(699,580)	(1,165,799)
Cash flows from financing activities:
Proceeds from / (repayment to) private placement					(50,000)	(25,000)
Proceeds from sales of common stock						98,627
Proceeds from convertible debt						983,175
Proceeds from short term loans, others					690,000	500,000
Repaid to note holders						(500,000)
Repaid to related party/others						(60,000)
Net cash provided by financing activities					640,000	996,802
Net increase (decrease) in cash					(59,580)	(168,997)
Cash and restricted cash - beginning of period		$ 261,452		$ 588,769	261,452	588,769	588,769
Cash and restricted cash - end of period	$ 201,872		$ 419,772		201,872	419,772	$ 261,452
Supplemental cash flow information:
Interest paid					197,458	328,181
Non-cash investing and financing activities:
Warrants issued in connection with private placement						2,905,316
Contribution from shareholder for payment of liabilities						644,463
Common shares issued upon conversion of debt					397,912	650,001
Beneficial Conversion Feature on convertible debt and restricted common shares						570,717
Adoption of ASU 2020-06, net					$ (209,323)

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2023

Description Of Business And Basis Of Presentation

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business

Fundraising

J.H. Darbie Financing Notes & Issuance of Oncotelic Warrants

Equity Purchase Agreement

August 2021 Notes

November-December 2021 and March 2022 Notes

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

May 2022 Note

In June 2022, Mast fully converted their November 2021 Note, for which the company issued 4,025,000 shares of Common Stock.

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

June 2022 Note

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements.

GMP Note purchase agreements and unsecured notes

Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $4.5 million.

For more information on the GMP debt financing, refer to Note 5 of the unaudited Notes to the Consolidated Financial Statements.

Joint Venture with GMP Bio

For more information on the JV, refer to Note 6 of the unaudited Notes to the Consolidated Financial Statements.

Pet2DAO

Principles of Consolidation

Basis of Presentation

Liquidity and Going Concern

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Cash

Debt issuance Costs and Debt discount

Fair Value of Financial Instruments

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

●

Investment in equity securities

			Cumulative		Cumulative
			Gross		Gross
	Initial		Unrealized		Unrealized		Fair
	Book Value		Gains		Losses		Value
June 30, 2023 and December 31, 2022
Investment in GMP Bio (equity securities)	$	22,640,519	$	-	$	-	$	22,640,519
Total	$	22,640,519	$	-	$	-	$	22,640,519

	June 30, 2023		December 31, 2022
Balance at January 1, 2023 and 2022	$	22,640,519	$	-
Contribution at cost basis		-		5,689,042
Gain on derecognition of non-financial asset		-		16,591,477
Change in fair value		-		-

Balance at June 30, 2023 and December 31, 2022	$	22,640,519	$	22,640,519

Derivative Liability

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of June 30, 2023 and 2022:

	June 30, 2023		June 30, 2022
	Conversion Feature		Conversion Feature
Balance at January 1, 2023 and 2022	$	198,140	$	340,290
New derivative liability				-
Reclassification to additional paid in capital from conversion of debt to common stock				-
Change in fair value		327,594		67,922

Balance at June, 2023 and 2022	$	525,734	$	408,212

	June 30, 2023			June 30, 2022
	Key			Key
	Assumptions			Assumptions
	for fair value			for fair value
	of conversions			of conversions
Risk free interest		5.4	%		0.17% -1.03%
Market price of share	$	0.03		$	0.17-0.23
Life of instrument in years		0.01			0.01 – 0.33
Volatility		171.25	%		107.50%-109.40%
Dividend yield		0	%		0	%

Net Income (Loss) Per Share

Stock-Based Compensation

Impairment of Long-Lived Assets

Intangible Assets

Goodwill

Derivative Financial Instruments Indexed to the Company’s Common Stock

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

Variable Interest Entity (VIE) Accounting

Investments - Equity Method

Joint Venture agreement

Embedded debt costs in convertible debt instruments

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (Topic 606).

Research & Development Costs

In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Recent Accounting Pronouncements

All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

INTANGIBLE ASSETS AND GOODWILL

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND GOODWILL

NOTE 3 - INTANGIBLE ASSETS AND GOODWILL

Goodwill from 2019 Reverse Merger with Oncotelic and PointR

Further, we added goodwill of $16,182,456 upon the completion of the Merger with PointR.

A summary of our goodwill as of June 30, 2023 and December 31, 2022 is shown below:

SUMMARY OF GOODWILL

	June 30,			December 31,
	2023			2022
Balance at beginning of the year	$	12,071,376		$	21,062,455
Less: Derecognition upon recording of gain on non-financial asset		-			(4,880,000	)
Less;: Goodwill impairment due to market capitalization		(6,083,146	)		(4,111,079	)

Balance at the end of the period	$	5,988,230		$	12,071,376

Assignment and Assumption Agreement with Autotelic, Inc.

Intangible Asset Summary

SCHEDULE OF INTANGIBLE ASSETS

	December 31, 2022			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual property	$	819,191
Intangible asset – Capitalization of license cost		190,989
		1,010,180
Less Accumulated Amortization		(201,180	)
Less: Derecognition of carrying value upon transfer of non-financial asset		(809,000	)
Total	$	-

There will be no future yearly amortization expense related to our intangibles.

In-Process Research & Development (“IPR&D”) Summary

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expense consists of the following amounts:

	June 30,		December 31,
	2023		2022
Accounts payable	$	1,682,943	$	1,735,764
Accrued expense		775,646		775,100
	$	2,458,589	$	2,510,864

	June 30, 2023		December 31, 2022

Accounts payable – related party	$	343,001	$	332,432

CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT

As of June 30, 2023 special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts:

	June 30,		December 31,
	2023		2022
Convertible debentures
10% Convertible note payable, due April 23, 2022 – Bridge Investor	$	35,556	$	35,556
10% Convertible note payable, due April 23, 2022 – Related Party		164,444		164,444
10% Convertible note payable, due August 6, 2022 – Bridge Investor		200,000		200,000
		400,000		400,000
Fall 2019 Notes
5% Convertible note payable – Stephen Boesch		126,458		123,958
5% Convertible note payable – Related Party		294,983		288,733
5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)		294,503		288,253
5% Convertible note payable – CEO, CTO* & CFO – Related Parties		96,509		94,457
5% Convertible note payable – Bridge Investors		197,722		193,522
		1,010,175		988,923
August 2021 Convertible Notes
5% Convertible note – Autotelic Inc– Related Party		273,802		267,553
5% Convertible note – Bridge investors		409,061		399,722
5% Convertible note – CFO – Related Party		82,142		80,266
		765,005		747,541
JH Darbie PPM Debt
16% Convertible Notes - Non-related parties		2,397,238		2,441,471
16% Convertible Notes – CEO – Related Party		125,000		124,547
		2,522,238		2,566,018
November/December 2021 & March 2022 Notes
16% Convertible Notes – Accredited Investors		323,622		619,345

Debt for Clinical Trials – GMP
2% Convertible Notes – GMP		4,704,631		4,659,782

May and June 2022 Note
16% Convertible Notes – Accredited Investors		1,286,809		885,312

Other Debt
Short term debt – Bridge investors		245,000		245,000
Short term debt from CFO		35,050		25,050
Short term debt – Autotelic Inc– Related Party		800,000		120,000
		1,080,050		390,050
Accrued interest		58,791		-
Total of convertible debentures & notes and other debt	$	12,133,821		11,256,971

Bridge Financing

Notes with Officer and Bridge Investor

Fall 2019 Debt Financing

The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of June 30, 2023, and December 31, 2022.

GMP Notes

Cumulatively, the GMP Note, GMP Note 2, October 2021 Note and the January 2022 Notes are referred to as the “GMP Notes”.

The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $4.7 million as of June 30, 2023, and December 31, 2022, respectively.

August 2021 Notes

As of June 30, 2023, and December 31, 2022, the August 2021 convertible notes, inclusive of accrued interest, consist of the following amounts:

	June 30,		December 31,
	2023		2022

Autotelic Related party convertible note, 5% coupon August 2022	$	273,802	$	267,553
CFO Related party convertible note, 5% coupon August 2022		409,061		399,722
Accredited investors convertible note, 5% coupon August 2022		82,142		80,266
	$	765,005	$	747,541

At June 30, 2023, and December 31, 2022, accrued interests on these convertible notes totaled approximately $66,500 and $49,040, respectively.

November – December 2021 and March 2022 Financing

As of June 30, 2023, and December 31, 2022, convertible notes under the November-December 2021 Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022
Blue Lake Partners LLC Convertible note, 16% coupon, December 2021 (In default and inclusive of accrued interest)		-			227,817
Fourth Man LLC Convertible note, 16% coupon December 2022 (In default and inclusive of accrued interest)		37,030			112,500
Convertible notes, gross	$	37,030		$	339,687
Less: Debt discount recorded		(500,000	)		(500,000	)
Amortization debt discount		500,000			500,000
Convertible notes, net	$	37,030		$	339,687

As of June 30, 2023, and December 31, 2022, Fourth Man convertible note, net of debt discount, consist of the following amounts:

	June 30,		December 31,
	2023		2022
Fourth Man Convertible note, 12% coupon March 2022 (Inclusive of interest and default provision)	$	286,593	$	340,959
Unamortized debt Discount		-		(61,301	)

Convertible notes, net	$	286,593	$	279,658

Accrued interest was approximately $8,400 and $22,800 at June 30, 2023 and December 31, 2022, respectively.

May 2022 Mast Financing

As of June 30, 2023, and December 31, 2022, the May 2022 Mast Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022

Mast Hill Convertible note, 16% coupon May 2023, inclusive of accrued interest and penalty	$	857,084		$	847,000
Convertible notes, gross	$	857,084		$	847,000
Less Debt discount recorded		(605,000	)		(605,000	)
Amortization debt discount, net of reversal of original and unamortized BCF		565,725			333,119
Convertible notes, net	$	817,809		$	575,119

June 2022 Financing

As of June 30, 2023, and December 31, 2022, convertible note under the June 2022 Blue Lake Financing, net of debt discount, consist of the following amounts:

	June 30,			December 31,
	2023			2022

Blue Lake Convertible note, 16% coupon June 2023, inclusive of accrued interest	$	469,000		$	469,000
Convertible notes, gross	$	469,000		$	469,000
Less Debt discount recorded		(332,748	)		(332,748	)
Amortization debt discount, net of reversal of original and unamortized BCF		332,748			173,941
Convertible notes, net	$	469,000		$	310,193

Other short-term advances

As of June 30, 2023 compared to December 31, 2022, other short-term advances consist of the following amounts obtained from various employees and related parties:

SCHEDULE OF SHORT-TERM LOANS

Other Advances	June 30, 2022		December 31, 2022
Short term advance from CFO – Related Party	$	35,050	$	25,050
Short term advances – bridge investors & others		245,000		245,000
Short term advance – Autotelic Inc. – Related Party		800,000		120,000
Short term advance	$	1,080,050	$	390,050

JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT

6 Months Ended

Jun. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT

NOTE 6 - JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT

For information on the various notes from GMP, refer to Note 5 – GMP Notes of the Notes to the Consolidated Financial Statements above.

PRIVATE PLACEMENT AND JH DARBIE FINANCING

6 Months Ended

Jun. 30, 2023

Private Placement And Jh Darbie Financing

PRIVATE PLACEMENT AND JH DARBIE FINANCING

NOTE 7 - PRIVATE PLACEMENT AND JH DARBIE FINANCING

	■	25,000 shares of Edge Point Common stock for a price of $1.00 per share of Edge Point Common stock.
	■	One convertible promissory note, convertible up to 25,000 shares of Edge Point Common stock, at a conversion price of $1.00 per share or up to 138,889 shares of the Company’s common stock, at a conversion price of $0.18 per share.
	■	50,000 warrants to purchase an equivalent number of shares of Edge Point Common stock at $1.00 per share and an equivalent number of shares of the Company’s common stock at $0.20 per share with a three-year expiration date. Either the Edgepoint or the Company’s warrants would be exercised.

As June 30, 2023 and December 31, 2022 funds received under the JH Darbie Financing, net of debt discount, consist of the following amounts:

	June 30, 2023		December 31, 2022
Convertible promissory notes
Subscription agreements - accredited investors	$	2,397,238	$	2,441,471
Subscription agreements – related party		125,000		124,547
Total convertible promissory notes	$	2,522,238	$	2,566,018

The terms of convertible notes are summarized as follows:

	■	Term: Through March 31, 2022, extended further to March 31, 2023
	■	Coupon: 16%.
	■	Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock.
	■	The conversion price is initially set at $0.18 per share for the Company’s Common Stock or $1.00 for Edgepoint Common Stock, subject to adjustment.

For more information on the private placement, refer to our 2022 Annual Report on Form 10-K filed with the SEC on April 19, 2023.

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2023

RELATED PARTY TRANSACTIONS

NOTE 8 - RELATED PARTY TRANSACTIONS

Master Service Agreement with Autotelic Inc.

Expenses related to the MSA were $0 for the three months ended June 30, 2023 as compared to approximately $1,000 for the same period of 2022.

License Agreement with Autotelic Inc.

Note Payable and Short-Term Loan – Related Parties

In May 2021, Autotelic provided an additional short-term funding of $250,000 to the Company, which was converted into the August 2021 Notes. Autotelic provided an additional $120,000 short term loan to the company during the year ended December 31, 2022. During the six months ended June 30, 2023 Autotelic provided $680,000 short term loan to the Company. As such, $800,000 was outstanding and payable to Autotelic at June 30, 2023.

Artius Consulting Agreement

No expense was recorded during the three and six months ended June 30, 2023 or 2022, respectively, related to this Agreement.

Maida Consulting Agreement

EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

6 Months Ended

Jun. 30, 2023

Equity Purchase Agreement And Registration Rights Agreement

EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

NOTE 9 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT

During the six months ended June 30, 2023, the Company did not sell any shares of Common Stock under the EPL.

STOCKHOLDERS’ EQUITY

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY